

PROTEINS BINDING CD33, NKG2D AND CD16

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62/461,145, filed February 20, 2017, the entire contents of which are
5 incorporated by reference herein for all purposes.

SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on February 19, 2018, is named DFY-007PC_SL.txt and is 98,304 bytes
10 in size.

FIELD OF THE INVENTION

[0003] The invention relates to multi-specific binding proteins that bind to CD33, the NKG2D receptor, and CD16.

BACKGROUND

15 [0004] Cancer continues to be a significant health problem despite the substantial research efforts and scientific advances reported in the literature for treating this disease. Some of the most frequently diagnosed cancers in adults include prostate cancer, breast cancer, and lung cancer. Hematological malignancies, though less frequent than solid cancers, have low survival rates. Current treatment options for these cancers are not effective
20 for all patients and/or can have substantial adverse side effects. Other types of cancer also remain challenging to treat using existing therapeutic options.

[0005] Cancer immunotherapies are desirable because they are highly specific and can facilitate destruction of cancer cells using the patient's own immune system. Fusion proteins such as bi-specific T-cell engagers are cancer immunotherapies described in the literature that
25 bind to tumor cells and T-cells to facilitate destruction of tumor cells. Antibodies that bind to certain tumor-associated antigens and to certain immune cells have been described in the literature. *See, e.g.*, WO 2016/134371 and WO 2015/095412.

[0006] Natural killer (NK) cells are a component of the innate immune system and make up approximately 15% of circulating lymphocytes. NK cells infiltrate virtually all tissues and
30 were originally characterized by their ability to kill tumor cells effectively without the need

for prior sensitization. Activated NK cells kill target cells by means similar to cytotoxic T cells – i.e. via cytolytic granules that contain perforin and granzymes as well as via death receptor pathways. Activated NK cells also secrete inflammatory cytokines such as IFN-gamma and chemokines that promote the recruitment of other leukocytes to the target tissue.

5 **[0007]** NK cells respond to signals through a variety of activating and inhibitory receptors on their surface. For example, when NK cells encounter healthy self-cells, their activity is inhibited through activation of the killer-cell immunoglobulin-like receptors (KIRs). Alternatively, when NK cells encounter foreign cells or cancer cells, they are activated via their activating receptors (*e.g.* NKG2D, NCRs, DNAM1). NK cells are also
10 activated by the constant region of some immunoglobulins through CD16 receptors on their surface. The overall sensitivity of NK cells to activation depends on the sum of stimulatory and inhibitory signals.

[0008] CD33 is a member of the sialic acid-binding immunoglobulin-like lectins. As a transmembrane receptor mainly expressed on cells of myeloid lineage, CD33 modulates
15 inflammatory and immune responses through a dampening effect on tyrosine kinase-driven signaling pathways. For example, CD33 was shown to constitutively suppress the production of pro-inflammatory cytokines such as IL-1 β , TNF- α , and IL-8 by human monocytes.

[0009] CD33 is associated with hematopoietic cancers. It is broadly expressed in blasts of nearly all acute myeloid leukemia (AML). Furthermore, hematopoietic cancer stem and/or
20 progenitor cells are found to be CD33⁺, implying that CD33-directed therapy could potentially eradicate malignant stem and/or progenitor cells in such cases while sparing normal hematopoietic stem cells. In addition to its expression in AML, CD33 is found on other myeloid neoplasms (*e.g.* myelodysplastic syndromes and myeloproliferative neoplasms) and on subsets of B-cell and T-cell acute lymphoblastic leukemias (ALL)/lymphoblastic
25 lymphomas. This expression pattern has led to the use of CD33-directed therapeutics in patients with malignancies including AML, myelodysplastic syndromes, chronic myelomonocytic leukemia, myeloid blast crisis of chronic myeloid leukemia, and ALLs.

SUMMARY

[0010] The invention provides multi-specific binding proteins that bind to CD33 on a
30 cancer cell and to the NKG2D receptor and CD16 receptor on natural killer cells. Such proteins can engage more than one kind of NK activating receptor, and may block the binding of natural ligands to NKG2D. In certain embodiments, the proteins can agonize NK cells in

humans, and in other species such as rodents and cynomolgus monkeys. Various aspects and embodiments of the invention are described in further detail below.

[0011] Accordingly, one aspect of the invention provides a protein that incorporates a first antigen-binding site that binds NKG2D; a second antigen-binding site that binds to
5 CD33; and an antibody Fc domain, a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16. The antigen-binding sites may each incorporate an antibody heavy chain variable domain and an antibody light chain variable domain, *e.g.*, arranged as in an antibody, or fused together to form an scFv, or one or more of the antigen-binding sites may be a single domain antibody, such as a V_HH antibody like a camelid
10 antibody or a V_{NAR} antibody like those found in cartilaginous fish.

[0012] The first antigen-binding site, which binds to NKG2D, in one embodiment, can incorporate a heavy chain variable domain related to SEQ ID NO:1, such as by having an amino acid sequence at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:1, and/or incorporating amino acid sequences
15 identical to the CDR1 (SEQ ID NO:54), CDR2 (SEQ ID NO:55), and CDR3 (SEQ ID NO:56) sequences of SEQ ID NO:1. Alternatively, the first antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:41 and a light chain variable domain related to SEQ ID NO:42. For example, the heavy chain variable domain of the first antigen binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%,
20 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:41, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:57), CDR2 (SEQ ID NO:58), and CDR3 (SEQ ID NO:59) sequences of SEQ ID NO:41. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:42, and/or incorporate amino acid
25 sequences identical to the CDR1 (SEQ ID NO:60), CDR2 (SEQ ID NO:61), and CDR3 (SEQ ID NO:62) sequences of SEQ ID NO:42. In other embodiments, the first antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:43 and a light chain variable domain related to SEQ ID NO:44. For example, the heavy chain variable domain of the first antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%,
30 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:43, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:63), CDR2 (SEQ ID NO:64), and CDR3 (SEQ ID NO:65) sequences of SEQ ID NO:43. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:44, and/or incorporate amino acid

sequences identical to the CDR1 (SEQ ID NO:66), CDR2 (SEQ ID NO:67), and CDR3 (SEQ ID NO:68) sequences of SEQ ID NO:44.

[0013] In some embodiments, the first antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:45 and a light chain variable domain related to SEQ ID NO:46, such as by having amino acid sequences at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:45 and at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:46 respectively. In another embodiment, the first antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:47 and a light chain variable domain related to SEQ ID NO:48, such as by having amino acid sequences at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:47 and at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:48 respectively.

[0014] In some embodiments, the first antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:69 and a light chain variable domain related to SEQ ID NO:70. For example, the heavy chain variable domain of the first antigen binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:69, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:71), CDR2 (SEQ ID NO:72), and CDR3 (SEQ ID NO:73) sequences of SEQ ID NO:69. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:70, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:74), CDR2 (SEQ ID NO:75), and CDR3 (SEQ ID NO:76) sequences of SEQ ID NO:70. In some embodiments, the first antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:77 and a light chain variable domain related to SEQ ID NO:78. For example, the heavy chain variable domain of the first antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:77, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:69), CDR2 (SEQ ID NO:80), and CDR3 (SEQ ID NO:81) sequences of SEQ ID NO:77. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:78, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:82), CDR2 (SEQ ID NO:83), and CDR3 (SEQ ID NO:84) sequences of SEQ ID NO:78.

[0015] In some embodiments, the first antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:85 and a light chain variable domain related to SEQ ID NO:86. For example, the heavy chain variable domain of the first antigen binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:85, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:87), CDR2 (SEQ ID NO:88), and CDR3 (SEQ ID NO:89) sequences of SEQ ID NO:85. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:86, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:90), CDR2 (SEQ ID NO:91), and CDR3 (SEQ ID NO:92) sequences of SEQ ID NO:86.

[0016] In some embodiments, the first antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:133 and a light chain variable domain related to SEQ ID NO:134. For example, the heavy chain variable domain of the first antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:133, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:135), CDR2 (SEQ ID NO:136), and CDR3 (SEQ ID NO:137) sequences of SEQ ID NO:133. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:134, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:138), CDR2 (SEQ ID NO:139), and CDR3 (SEQ ID NO:140) sequences of SEQ ID NO:134.

[0017] The second antigen-binding site can optionally incorporate a heavy chain variable domain related to SEQ ID NO:93 and a light chain variable domain related to SEQ ID NO:94. For example, the heavy chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:93, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:95), CDR2 (SEQ ID NO:96), and CDR3 (SEQ ID NO:97) sequences of SEQ ID NO:93. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:94 and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:98), CDR2 (SEQ ID NO:99), and CDR3 (SEQ ID NO:100) sequences of SEQ ID NO:94.

[0018] Alternatively, the second antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:101 and a light chain variable domain related to SEQ ID NO:102. For example, the heavy chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:101, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:103), CDR2 (SEQ ID NO:104), and CDR3 (SEQ ID NO:105) sequences of SEQ ID NO:101. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:58, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:106), CDR2 (SEQ ID NO:107), and CDR3 (SEQ ID NO:108) sequences of SEQ ID NO:102.

[0019] In another embodiment, the second antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:109 and a light chain variable domain related to SEQ ID NO:110. For example, the heavy chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:59, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:111), CDR2 (SEQ ID NO:112), and CDR3 (SEQ ID NO:113) sequences of SEQ ID NO:109. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:110, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:114), CDR2 (SEQ ID NO:115), and CDR3 (SEQ ID NO:116) sequences of SEQ ID NO:110.

[0020] In another embodiment, the second antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:117 and a light chain variable domain related to SEQ ID NO:118. For example, the heavy chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:117, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:119), CDR2 (SEQ ID NO:120), and CDR3 (SEQ ID NO:121) sequences of SEQ ID NO:117. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:118, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:122), CDR2 (SEQ ID NO:123), and CDR3 (SEQ ID NO:124) sequences of SEQ ID NO:118.

[0021] In another embodiment, the second antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:125 and a light chain variable domain related to SEQ ID NO:126. For example, the heavy chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
5 99%, or 100%) identical to SEQ ID NO:125, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:127), CDR2 (SEQ ID NO:128), and CDR3 (SEQ ID NO:129) sequences of SEQ ID NO:125. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:126, and/or incorporate amino acid
10 sequences identical to the CDR1 (SEQ ID NO:130), CDR2 (SEQ ID NO:131), and CDR3 (SEQ ID NO:132) sequences of SEQ ID NO:126.

[0022] In some embodiments, the second antigen-binding site incorporates a light chain variable domain having an amino acid sequence identical to the amino acid sequence of the light chain variable domain present in the first antigen-binding site.

15 [0023] In some embodiments, the protein incorporates a portion of an antibody Fc domain sufficient to bind CD16, wherein the antibody Fc domain comprises hinge and CH2 domains, and/or amino acid sequences at least 90% identical to amino acid sequence 234-332 of a human IgG antibody.

[0024] Formulations containing one of these proteins; cells containing one or more
20 nucleic acids expressing these proteins, and methods of enhancing tumor cell death using these proteins are also provided.

[0025] Another aspect of the invention provides a method of treating cancer in a patient. The method comprises administering to a patient in need thereof a therapeutically effective amount of the multi-specific binding protein described herein. Exemplary cancers for
25 treatment using the multi-specific binding proteins include, for example, wherein the cancer is selected from the group consisting of AML, myelodysplastic syndromes, chronic myelomonocytic leukemia, myeloid blast crisis of chronic myeloid leukemia, and ALLs.

BRIEF DESCRIPTION OF THE DRAWINGS

[0026] **FIG. 1** is a representation of a heterodimeric, multi-specific antibody. Each arm
30 can represent either the NKG2D-binding domain or CD33-binding domain. In some embodiments, the NKG2D- and CD33-binding domains can share a common light chain.

[0027] **FIG. 2** is a representation of a heterodimeric, multi-specific antibody. Either the NKG2D- or CD33-binding domain can take the scFv format (right arm).

[0028] **FIG. 3** are line graphs demonstrating the binding affinity of NKG2D-binding domains (listed as clones) to human recombinant NKG2D in an ELISA assay.

5 [0029] **FIG. 4** are line graphs demonstrating the binding affinity of NKG2D-binding domains (listed as clones) to cynomolgus recombinant NKG2D in an ELISA assay.

[0030] **FIG. 5** are line graphs demonstrating the binding affinity of NKG2D-binding domains (listed as clones) to mouse recombinant NKG2D in an ELISA assay.

[0031] **FIG. 6** are bar graphs demonstrating the binding of NKG2D-binding domains (listed as clones) to EL4 cells expressing human NKG2D by flow cytometry showing mean fluorescence intensity (MFI) fold over background.

10 [0032] **FIG. 7** are bar graphs demonstrating the binding of NKG2D-binding domains (listed as clones) to EL4 cells expressing mouse NKG2D by flow cytometry showing mean fluorescence intensity (MFI) fold over background.

15 [0033] **FIG. 8** are line graphs demonstrating specific binding affinity of NKG2D-binding domains (listed as clones) to recombinant human NKG2D-Fc by competing with natural ligand ULBP-6.

[0034] **FIG. 9** are line graphs demonstrating specific binding affinity of NKG2D-binding domains (listed as clones) to recombinant human NKG2D-Fc by competing with natural

20 ligand MICA.

[0035] **FIG. 10** are line graphs demonstrating specific binding affinity of NKG2D-binding domains (listed as clones) to recombinant mouse NKG2D-Fc by competing with natural ligand Rae-1 delta.

[0036] **FIG. 11** are bar graphs showing activation of human NKG2D by NKG2D-binding domains (listed as clones) by quantifying the percentage of TNF-alpha positive cells, which

25 express human NKG2D-CD3 zeta fusion proteins.

[0037] **FIG. 12** are bar graphs showing activation of mouse NKG2D by NKG2D-binding domains (listed as clones) by quantifying the percentage of TNF-alpha positive cells, which express mouse NKG2D-CD3 zeta fusion proteins.

30 [0038] **FIG. 13** are bar graphs showing activation of human NK cells by NKG2D-binding domains (listed as clones).

[0039] **FIG. 14** are bar graphs showing activation of human NK cells by NKG2D-binding domains (listed as clones).

[0040] FIG. 15 are bar graphs showing activation of mouse NK cells by NKG2D-binding domains (listed as clones).

[0041] FIG. 16 are bar graphs showing activation of mouse NK cells by NKG2D-binding domains (listed as clones).

5 [0042] FIG. 17 are bar graphs showing the cytotoxic effect of NKG2D-binding domains (listed as clones) on tumor cells.

[0043] FIG. 18 are bar graphs showing the melting temperature of NKG2D-binding domains (listed as clones) measured by differential scanning fluorimetry.

[0044] FIGS. 19A-19C are bar graphs of synergistic activation of NK cells using CD16 and NKG2D binding. FIG. 19A demonstrates levels of CD107a; FIG. 19B demonstrates levels of IFN γ ; FIG. 19C demonstrates levels of CD107a and IFN γ . Graphs indicate the mean (n = 2) $\pm$ SD. Data are representative of five independent experiments using five different healthy donors.

10 [0045] FIG. 20 is a representation of a TriNKET in the Triomab form, which is a trifunctional, bispecific antibody that maintains an IgG-like shape. This chimera consists of two half antibodies, each with one light and one heavy chain, that originate from two parental antibodies. Triomab form may be an heterodimeric construct containing 1/2 of rat antibody and 1/2 of mouse antibody.

[0046] FIG. 21 is a representation of a TriNKET in the KiH Common Light Chain (LC) form, which involves the knobs-into-holes (KIHs) technology. KiH is a heterodimer containing 2 Fabs binding to target 1 and 2, and an Fc stabilized by heterodimerization mutations. TriNKET in the KiH format may be an heterodimeric construct with 2 fabs binding to target 1 and target 2, containing two different heavy chains and a common light chain that pairs with both heavy chains.

20 [0047] FIG. 22 is a representation of a TriNKET in the dual-variable domain immunoglobulin (DVD-IgTM) form, which combines the target binding domains of two monoclonal antibodies via flexible naturally occurring linkers, and yields a tetravalent IgG-like molecule. DVD-IgTM is an homodimeric construct where variable domain targeting antigen 2 is fused to the N terminus of variable domain of Fab targeting antigen 1 Construct contains normal Fc.

25 [0048] FIG. 23 is a representation of a TriNKET in the Orthogonal Fab interface (Ortho-Fab) form, which is an heterodimeric construct that contains 2 Fabs binding to target1 and target 2 fused to Fc. LC-HC pairing is ensured by orthogonal interface. Heterodimerization is ensured by mutations in the Fc.

30

[0049] **FIG. 24** is a representation of a TrinKET in the 2-in-1 Ig format.

[0050] **FIG. 25** is a representation of a TrinKET in the ES form, which is an heterodimeric construct containing two different Fabs binding to target 1 and target 2 fused to the Fc. Heterodimerization is ensured by electrostatic steering mutations in the Fc.

5 [0051] **FIG. 26** is a representation of a TrinKET in the Fab Arm Exchange form: antibodies that exchange Fab arms by swapping a heavy chain and attached light chain (half-molecule) with a heavy-light chain pair from another molecule, resulting in bispecific antibodies. Fab Arm Exchange form (cFae) is a heterodimer containing 2 Fabs binding to target 1 and 2, and an Fc stabilized by heterodimerization mutations.

10 [0052] **FIG. 27** is a representation of a TrinKET in the SEED Body form, which is an heterodimer containing 2 Fabs binding to target 1 and 2, and an Fc stabilized by heterodimerization mutations.

[0053] **FIG. 28** is a representation of a TrinKET in the LuZ-Y form, in which leucine zipper is used to induce heterodimerization of two different HCs. LuZ-Y form is a

15 heterodimer containing two different scFabs binding to target 1 and 2, fused to Fc. Heterodimerization is ensured through leucine zipper motifs fused to C-terminus of Fc.

[0054] **FIG. 29** is a representation of a TrinKET in the Cov-X-Body form.

[0055] **FIGs. 30A-30B** are representations of TrinKETs in the $\kappa\lambda$ -Body forms, which are an heterodimeric constructs with two different Fabs fused to Fc stabilized by

20 heterodimerization mutations: Fab1 targeting antigen 1 contains kappa LC, while second Fab targeting antigen 2 contains lambda LC. FIG. 30A is an exemplary representation of one form of a $\kappa\lambda$ -Body; FIG. 30B is an exemplary representation of another $\kappa\lambda$ -Body.

[0056] **FIG. 31** is an Oasc-Fab heterodimeric construct that includes Fab binding to target 1 and scFab binding to target 2 fused to Fc. Heterodimerization is ensured by mutations

25 in the Fc.

[0057] **FIG. 32** is a DuetMab, which is an heterodimeric construct containing two different Fabs binding to antigens 1 and 2, and Fc stabilized by heterodimerization mutations. Fab 1 and 2 contain differential S-S bridges that ensure correct light chain (LC) and heavy chain (HC) pairing.

30 [0058] **FIG. 33** is a CrossmAb, which is an heterodimeric construct with two different Fabs binding to targets 1 and 2 fused to Fc stabilized by heterodimerization. CL and CH1 domains and VH and VL domains are switched, *e.g.*, CH1 is fused in-line with VL, while CL is fused in-line with VH.

[0059] **FIG. 34** is a Fit-Ig, which is an homodimeric constructs where Fab binding to antigen 2 is fused to the N terminus of HC of Fab that binds to antigen 1. The construct contains wild-type Fc.

[0060] **FIG. 35A-35B** are binding profiles of CD33-targeting TriNKETs to NKG2D expressed on EL4 cells. FIG. 35A shows binding of the TriNKETs in comparison with the monoclonal antibodies which contain the corresponding NKG2D binding domain. FIG. 35B shows the binding profile of CD33-targeting TriNKETs which include 6 different NKG2D binding domains.

[0061] **FIGs. 36A and 36B** are binding profiles of CD33-targeting TriNKETs to CD33 expressed on MV4-11 human AML cells. **FIG. 36C** is a binding profile of CD33-targeting TriNKETs and CD33 monoclonal antibody to CD33 expressed on Molm-13 human AML cells. **FIG. 36D** is binding profile of CD33-targeting TriNKETs and CD33 monoclonal antibody to CD33 expressed on human AML cell line MV4-11.

[0062] **FIGs. 37A – 37B** are line graphs demonstrating TriNKET-mediated activation of rested or IL-2-activated human NK cells in co-culture with the CD33-expressing human AML cell line MV4-11. FIG. 37A shows TriNKET-mediated activation of resting human NK cells. FIG. 37B shows TriNKET-mediated activation of IL-2-activated human NK cells from the same donor. NK cells alone, NK cells co-culturing with MV4-11 cells but without TriNKETs, and a CD20-targeting TriNKET were used controls.

[0063] **FIGs. 38A – 38C** are histograms showing that expression of the high-affinity FcR γ I (CD64) on three human AML cells lines, Molm-13 cell line (FIG. 38A), MV4-11 cell line (FIG. 38B), and THP-1 cell line (FIG. 38C).

[0064] **FIGs. 39A - 39B** are line graphs of CD33 monoclonal antibody or TriNKETs mediated activation of human NK cells in co-culture with either Molm-13 (FIG. 39B) or THP-1 (FIG. 39A) cells. **FIG. 39C** shows activation of human NK cells by TriNKETs in co-culture with MV4-11 human AML cell line. HER2-TriNKET was used as a control.

[0065] **FIGs. 40A – 40C** are line graphs of human NK cytotoxicity towards three human AML cell lines mediated by CD33-targeting TriNKETs and the corresponding CD33 monoclonal antibody. FIG. 40A shows that CD33 monoclonal antibody showed reduced efficacy towards MV4-11 cells, which express CD64, but at a lower level than THP-1. FIG. 40B demonstrates that CD33 monoclonal antibody showed good efficacy towards Molm-13 cells, which do not express CD64. FIG. 40C demonstrates that CD33 monoclonal antibody showed no effect on THP-1 cells.

[0066] FIG. 41 shows TriNKETs-mediated cytotoxicity of rested human NK cells towards Molm-13 cells.

[0067] FIG. 42A is a bar graph showing that B cells from a health donor are protected from CD33-targeting TriNKET-mediated lysis. FIG. 42B is a bar graph showing that autologous CD33+ myeloid cells were protected from CD33-targeting TriNKET-mediated NK cell responses, and, therefore, were resistant to TriNKET-mediated lysis.

DETAILED DESCRIPTION

[0068] The invention provides multi-specific binding proteins that bind CD33 on a cancer cell and the NKG2D receptor and CD16 receptor on natural killer cells to activate the natural killer cells, pharmaceutical compositions comprising such multi-specific binding proteins, and therapeutic methods using such multi-specific proteins and pharmaceutical compositions, including for the treatment of cancer. Various aspects of the invention are set forth below in sections; however, aspects of the invention described in one particular section are not to be limited to any particular section.

[0069] To facilitate an understanding of the present invention, a number of terms and phrases are defined below.

[0070] The terms "a" and "an" as used herein mean "one or more" and include the plural unless the context is inappropriate.

[0071] As used herein, the term "antigen-binding site" refers to the part of the immunoglobulin molecule that participates in antigen binding. In human antibodies, the antigen binding site is formed by amino acid residues of the N-terminal variable ("V") regions of the heavy ("H") and light ("L") chains. Three highly divergent stretches within the V regions of the heavy and light chains are referred to as "hypervariable regions" which are interposed between more conserved flanking stretches known as "framework regions," or "FR." Thus the term "FR" refers to amino acid sequences which are naturally found between and adjacent to hypervariable regions in immunoglobulins. In a human antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface. The antigen-binding surface is complementary to the three-dimensional surface of a bound antigen, and the three hypervariable regions of each of the heavy and light chains are referred to as "complementarity-determining regions," or "CDRs." In certain animals, such as camels and cartilaginous fish, the antigen-binding site is formed by a single

antibody chain providing a “single domain antibody.” Antigen-binding sites can exist in an intact antibody, in an antigen-binding fragment of an antibody that retains the antigen-binding surface, or in a recombinant polypeptide such as an scFv, using a peptide linker to connect the heavy chain variable domain to the light chain variable domain in a single polypeptide.

[0072] The term “tumor associated antigen” as used herein means any antigen including but not limited to a protein, glycoprotein, ganglioside, carbohydrate, lipid that is associated with cancer. Such antigen can be expressed on malignant cells or in the tumor microenvironment such as on tumor-associated blood vessels, extracellular matrix, mesenchymal stroma, or immune infiltrates.

[0073] As used herein, the terms “subject” and “patient” refer to an organism to be treated by the methods and compositions described herein. Such organisms preferably include, but are not limited to, mammals (*e.g.*, murines, simians, equines, bovines, porcines, canines, felines, and the like), and more preferably include humans.

[0074] As used herein, the term “effective amount” refers to the amount of a compound (*e.g.*, a compound of the present invention) sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route. As used herein, the term “treating” includes any effect, *e.g.*, lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.

[0075] As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use *in vivo* or *ex vivo*.

[0076] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (*e.g.*, such as an oil/water or water/oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, *see, e.g.*, Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA [1975].

[0077] As used herein, the term “pharmaceutically acceptable salt” refers to any pharmaceutically acceptable salt (*e.g.*, acid or base) of a compound of the present invention

which, upon administration to a subject, is capable of providing a compound of this invention or an active metabolite or residue thereof. As is known to those of skill in the art, "salts" of the compounds of the present invention may be derived from inorganic or organic acids and bases. Exemplary acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

[0078] Exemplary bases include, but are not limited to, alkali metal (*e.g.*, sodium) hydroxides, alkaline earth metal (*e.g.*, magnesium) hydroxides, ammonia, and compounds of formula NW_4^+ , wherein W is C_{1-4} alkyl, and the like.

[0079] Exemplary salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, undecanoate, and the like. Other examples of salts include anions of the compounds of the present invention compounded with a suitable cation such as Na^+ , NH_4^+ , and NW_4^+ (wherein W is a C_{1-4} alkyl group), and the like.

[0080] For therapeutic use, salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable. However, salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.

[0081] Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited

components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.

[0082] As a general matter, compositions specifying a percentage are by weight unless otherwise specified. Further, if a variable is not accompanied by a definition, then the previous definition of the variable controls.

I. PROTEINS

[0083] The invention provides multi-specific binding proteins that bind CD33 on a cancer cell and the NKG2D receptor and CD16 receptor on natural killer cells to activate the natural killer cell. The multi-specific binding proteins are useful in the pharmaceutical compositions and therapeutic methods described herein. Binding of the multi-specific binding protein to the NKG2D receptor and CD16 receptor on natural killer cell enhances the activity of the natural killer cell toward destruction of a cancer cell. Binding of the multi-specific binding protein to CD33 on a cancer cell brings the cancer cell into proximity to the natural killer cell, which facilitates direct and indirect destruction of the cancer cell by the natural killer cell. Further description of exemplary multi-specific binding proteins is provided below.

[0084] The first component of the multi-specific binding proteins binds to NKG2D receptor-expressing cells, which can include but are not limited to NK cells, $\gamma\delta$ T cells and $CD8^+ \alpha\beta$ T cells. Upon NKG2D binding, the multi-specific binding proteins may block natural ligands, such as ULBP6 and MICA, from binding to NKG2D and activating NKG2D receptors.

[0085] The second component of the multi-specific binding proteins binds to CD33-expressing cells, which can include but are not limited to AML, myelodysplastic syndromes, chronic myelomonocytic leukemia, myeloid blast crisis of chronic myeloid leukemia, and ALLs.

[0086] The third component for the multi-specific binding proteins binds to cells expressing CD16, a Fc receptor on the surface of leukocytes including natural killer cells, macrophages, neutrophils, eosinophils, mast cells, and follicular dendritic cells.

[0087] The multi-specific binding proteins described herein can take various formats. For example, one format is a heterodimeric, multi-specific antibody including a first immunoglobulin heavy chain, a first immunoglobulin light chain, a second immunoglobulin heavy chain and a second immunoglobulin light chain (FIG. 1). The first immunoglobulin heavy chain includes a first Fc (hinge-CH2-CH3) domain, a first heavy chain variable domain

and optionally a first CH1 heavy chain domain. The first immunoglobulin light chain includes a first light chain variable domain and a first light chain constant domain. The first immunoglobulin light chain, together with the first immunoglobulin heavy chain, forms an antigen-binding site that binds NKG2D. The second immunoglobulin heavy chain comprises
5 a second Fc (hinge-CH2-CH3) domain, a second heavy chain variable domain and optionally a second CH1 heavy chain domain. The second immunoglobulin light chain includes a second light chain variable domain and a second light chain constant domain. The second immunoglobulin light chain, together with the second immunoglobulin heavy chain, forms an antigen-binding site that binds CD33. The first Fc domain and second Fc domain together are
10 able to bind to CD16 (FIG. 1). In some embodiments, the first immunoglobulin light chain can be identical to the second immunoglobulin light chain.

[0088] Another exemplary format involves a heterodimeric, multi-specific antibody including a first immunoglobulin heavy chain, a second immunoglobulin heavy chain and an immunoglobulin light chain (FIG. 2). The first immunoglobulin heavy chain includes a first
15 Fc (hinge-CH2-CH3) domain fused via either a linker or an antibody hinge to a single-chain variable fragment (scFv) composed of a heavy variable domain and light chain variable domain which pair and bind NKG2D or CD33. The second immunoglobulin heavy chain includes a second Fc (hinge-CH2-CH3) domain, a second heavy chain variable domain and optionally a CH1 heavy chain domain. The immunoglobulin light chain includes a light chain
20 variable domain and a constant light chain domain. The second immunoglobulin heavy chain pairs with the immunoglobulin light chain and binds to NKG2D or CD33. The first Fc domain and the second Fc domain together are able to bind to CD16 (FIG. 2).

[0089] One or more additional binding motifs may be fused to the C-terminus of the constant region CH3 domain, optionally via a linker sequence. In certain embodiments, the
25 antigen-binding site could be a single-chain or disulfide-stabilized variable region (scFv) or could form a tetravalent or trivalent molecule.

[0090] In some embodiments, the multi-specific binding protein is in the Triomab form, which is a trifunctional, bispecific antibody that maintains an IgG-like shape. This chimera consists of two half antibodies, each with one light and one heavy chain, that originate from
30 two parental antibodies.

[0091] In some embodiments, the multi-specific binding protein is the KiH Common Light Chain (LC) form, which involves the knobs-into-holes (KIHs) technology. The KIH

involves engineering C_H3 domains to create either a “knob” or a “hole” in each heavy chain to promote heterodimerization. The concept behind the “Knobs-into-Holes (KiH)” Fc technology was to introduce a “knob” in one CH3 domain (CH3A) by substitution of a small residue with a bulky one (*e.g.*, T366W_{CH3A} in EU numbering). To accommodate the “knob,”

5 a complementary “hole” surface was created on the other CH3 domain (CH3B) by replacing the closest neighboring residues to the knob with smaller ones (*e.g.*, T366S/L368A/Y407V_{CH3B}). The “hole” mutation was optimized by structured-guided phage library screening (Atwell S, Ridgway JB, Wells JA, Carter P., Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library, *J. Mol.*

10 *Biol.* (1997) 270(1):26–35). X-ray crystal structures of KiH Fc variants (Elliott JM, Ultsch M, Lee J, Tong R, Takeda K, Spiess C, *et al.*, Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction. *J. Mol. Biol.* (2014) 426(9):1947–57; Mimoto F, Kadono S, Katada H, Igawa T, Kamikawa T, Hattori K. Crystal structure of a novel asymmetrically engineered Fc variant

15 with improved affinity for Fcγ₁Rs. *Mol. Immunol.* (2014) 58(1):132–8) demonstrated that heterodimerization is thermodynamically favored by hydrophobic interactions driven by steric complementarity at the inter-CH3 domain core interface, whereas the knob–knob and the hole–hole interfaces do not favor homodimerization owing to steric hindrance and disruption of the favorable interactions, respectively.

20 **[0092]** In some embodiments, the multi-specific binding protein is in the dual-variable domain immunoglobulin (DVD-IgTM) form, which combines the target binding domains of two monoclonal antibodies via flexible naturally occurring linkers, and yields a tetravalent IgG-like molecule.

[0093] In some embodiments, the multi-specific binding protein is in the Orthogonal Fab interface (Ortho-Fab) form. In the ortho-Fab IgG approach (Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, *et al.*, Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. *Nat. Biotechnol.* (2014) 32(2):191–8), structure-based regional design introduces complementary mutations at the LC and HC_{VH-CH1} interface in only one Fab, without any changes being made to the other Fab.

25 **[0094]** In some embodiments, the multi-specific binding protein is in the 2-in-1 Ig format. In some embodiments, the multi-specific binding protein is in the ES form, which is a heterodimeric construct containing two different Fabs binding to targets 1 and target 2 fused to the Fc. Heterodimerization is ensured by electrostatic steering mutations in the Fc. In some

30

embodiments, the multi-specific binding protein is in the $\kappa\lambda$ -Body form, which is an heterodimeric constructs with two different Fabs fused to Fc stabilized by heterodimerization mutations: Fab1 targeting antigen 1 contains kappa LC, while second Fab targeting antigen 2 contains lambda LC. FIG. 30A is an exemplary representation of one form of a $\kappa\lambda$ -Body;
5 FIG. 30B is an exemplary representation of another $\kappa\lambda$ -Body.

[0095] In some embodiments, the multi-specific binding protein is in Fab Arm Exchange form (antibodies that exchange Fab arms by swapping a heavy chain and attached light chain (half-molecule) with a heavy-light chain pair from another molecule, which results in bispecific antibodies). In some embodiments, the multi-specific binding protein is in the
10 SEED Body form. The strand-exchange engineered domain (SEED) platform was designed to generate asymmetric and bispecific antibody-like molecules, a capability that expands therapeutic applications of natural antibodies. This protein engineered platform is based on exchanging structurally related sequences of immunoglobulin within the conserved CH3 domains. The SEED design allows efficient generation of AG/GA heterodimers, while
15 disfavoring homodimerization of AG and GA SEED CH3 domains. (Muda M. *et al.*, *Protein Eng. Des. Sel.* (2011, 24(5):447-54)). In some embodiments, the multi-specific binding protein is in the LuZ-Y form, in which a leucine zipper is used to induce heterodimerization of two different HCs. (Wranik, BJ. *et al.*, *J. Biol. Chem.* (2012), 287:43331-9).

[0096] In some embodiments, the multi-specific binding protein is in the Cov-X-Body
20 form. In bispecific CovX-Bodies, two different peptides are joined together using a branched azetidinone linker and fused to the scaffold antibody under mild conditions in a site-specific manner. Whereas the pharmacophores are responsible for functional activities, the antibody scaffold imparts long half-life and Ig-like distribution. The pharmacophores can be chemically optimized or replaced with other pharmacophores to generate optimized or unique
25 bispecific antibodies. (Doppalapudi VR *et al.*, *PNAS* (2010), 107(52);22611-22616).

[0097] In some embodiments, the multi-specific binding protein is in an Oasc-Fab heterodimeric form that includes Fab binding to target 1, and scFab binding to target 2 fused to Fc. Heterodimerization is ensured by mutations in the Fc.

[0098] In some embodiments, the multi-specific binding protein is in a DuetMab form,
30 which is an heterodimeric construct containing two different Fabs binding to antigens 1 and 2, and Fc stabilized by heterodimerization mutations. Fab 1 and 2 contain differential S-S bridges that ensure correct LC and HC pairing.

[0099] In some embodiments, the multi-specific binding protein is in a CrossmAb form, which is an heterodimeric construct with two different Fabs binding to targets 1 and 2, fused to Fc stabilized by heterodimerization. CL and CH1 domains and VH and VL domains are switched, *e.g.*, CH1 is fused in-line with VL, while CL is fused in-line with VH.

5 **[00100]** In some embodiments, the multi-specific binding protein is in a Fit-Ig form, which is an homodimeric constructs where Fab binding to antigen 2 is fused to the N terminus of HC of Fab that binds to antigen 1. The construct contains wild-type Fc.

[00101] Table 1 lists peptide sequences of heavy chain variable domains and light chain variable domains that, in combination, can bind to NKG2D. The NKG2D binding domains
10 can vary in their binding affinity to NKG2D, nevertheless, they all activate human NKG2D and NK cells.

Table 1		
Clones	Heavy chain variable region amino acid sequence	Light chain variable region amino acid sequence
ADI-27705	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKS RVTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPPWGQGT LTVSS (SEQ ID NO:1) CDR1 (SEQ ID NO:54) – GSFSGYYWS CDR2 (SEQ ID NO:55) – EIDHSGSTNYNPSLKS CDR3 (SEQ ID NO:56) – ARARGPWSFDP	DIQMTQSPSTLSASVGDRVITTCR ASQSISSWLAWYQQKPGKAPKLL IYKASSLES GVP SRFSGSGSGTEFT LTISSLQPDDFATYYCQQYNSYPI TFGGGTKVEIK (SEQ ID NO:2)
ADI-27724	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKS RVTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPPWGQGT LTVSS (SEQ ID NO:3)	EIVLTQSPGTLSPGERATLSCRA SQSVSSSYLAWYQQKPGQAPRLL IYGASSRATGIPDRFSGSGSGTDFT LTISRLEPEDFAVYYCQQYGSSPIT FGGGTKVEIK (SEQ ID NO:4)
ADI-27740	QVQLQQWGAGLLKPSETLSLTCAVY	DIQMTQSPSTLSASVGDRVITTCR

(A40)	GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRVTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPWGQGTLVTVSS (SEQ ID NO:5)	ASQSIGSWLAWYQQKPGKAPKLL IYKASSLESGVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQQYHSFYT FGGGTKVEIK (SEQ ID NO:6)
ADI-27741	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRVTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPWGQGTLVTVSS (SEQ ID NO:7)	DIQMTQSPSTLSASVGDRVITICR ASQSIGSWLAWYQQKPGKAPKLL IYKASSLESGVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQQSNSYYT FGGGTKVEIK (SEQ ID NO:8)
ADI-27743	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRVTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPWGQGTLVTVSS (SEQ ID NO:9)	DIQMTQSPSTLSASVGDRVITICR ASQSISSWLAWYQQKPGKAPKLL IYKASSLESGVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQQYNSYPT FGGGTKVEIK (SEQ ID NO:10)
ADI-28153	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRVTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW GFDPWGQGTLVTVSS (SEQ ID NO:11)	ELQMTQSPSSLSASVGDRVITICR TSQSISSYLNWYQQKPGQPPKLLI YWASTRESGVDPDRFSGSGSGTDFT LTISSLQPEDSATYYCQQSYDIP YTFGQGTKLEIK (SEQ ID NO:12)
ADI-28226 (C26)	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRVTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPWGQGTLVTVSS (SEQ ID NO:13)	DIQMTQSPSTLSASVGDRVITICR ASQSISSWLAWYQQKPGKAPKLL IYKASSLESGVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQQYGSFPIT FGGGTKVEIK (SEQ ID NO:14)
ADI-28154	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRVTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW	DIQMTQSPSTLSASVGDRVITICR ASQSISSWLAWYQQKPGKAPKLL IYKASSLESGVPSRFSGSGSGTDFT LTISSLQPDDFATYYCQQSKEVP

	SFDPWGQGTSLTVTVSS (SEQ ID NO:15)	WTFGQGTKVEIK (SEQ ID NO:16)
ADI-29399	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPWGQGTSLTVTVSS (SEQ ID NO:17)	DIQMTQSPSTLSASVGDRVITTCR ASQSISSWLAWYQQKPGKAPKLL IYKASSLESGVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQQYNSFPT FGGGTKVEIK (SEQ ID NO:18)
ADI-29401	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPWGQGTSLTVTVSS (SEQ ID NO:19)	DIQMTQSPSTLSASVGDRVITTCR ASQSIGSWLAWYQQKPGKAPKLL IYKASSLESGVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQQYDIYPT FGGGTKVEIK (SEQ ID NO:20)
ADI-29403	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPWGQGTSLTVTVSS (SEQ ID NO:21)	DIQMTQSPSTLSASVGDRVITTCR ASQSISSWLAWYQQKPGKAPKLL IYKASSLESGVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQQYDSYPT FGGGTKVEIK (SEQ ID NO:22)
ADI-29405	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPWGQGTSLTVTVSS (SEQ ID NO:23)	DIQMTQSPSTLSASVGDRVITTCR ASQSISSWLAWYQQKPGKAPKLL IYKASSLESGVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQQYGSFPT FGGGTKVEIK (SEQ ID NO:24)
ADI-29407	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPWGQGTSLTVTVSS (SEQ ID NO:25)	DIQMTQSPSTLSASVGDRVITTCR ASQSISSWLAWYQQKPGKAPKLL IYKASSLESGVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQQYQSFP FGGGTKVEIK (SEQ ID NO:26)
ADI-29419	QVQLQQWGAGLLKPSETLSLTCAVY	DIQMTQSPSTLSASVGDRVITTCR

	GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPWGQGT LTVSS (SEQ ID NO:27)	ASQSISSWLAWYQQKPGKAPKLL IYKASSLESVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQQYSSFST FGGGTKVEIK (SEQ ID NO:28)
ADI-29421	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPWGQGT LTVSS (SEQ ID NO:29)	DIQMTQSPSTLSASVGDRVITCR ASQSISSWLAWYQQKPGKAPKLL IYKASSLESVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQQYESYST FGGGTKVEIK (SEQ ID NO:30)
ADI-29424	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPWGQGT LTVSS (SEQ ID NO:31)	DIQMTQSPSTLSASVGDRVITCR ASQSISSWLAWYQQKPGKAPKLL IYKASSLESVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQQYDSFITF GGGTKVEIK (SEQ ID NO:32)
ADI-29425	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPWGQGT LTVSS (SEQ ID NO:33)	DIQMTQSPSTLSASVGDRVITCR ASQSISSWLAWYQQKPGKAPKLL IYKASSLESVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQQYQSYPT FGGGTKVEIK (SEQ ID NO:34)
ADI-29426	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPWGQGT LTVSS (SEQ ID NO:35)	DIQMTQSPSTLSASVGDRVITCR ASQSIGSWLAWYQQKPGKAPKLL IYKASSLESVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQQYHSFPT FGGGTKVEIK (SEQ ID NO:36)
ADI-29429	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW	DIQMTQSPSTLSASVGDRVITCR ASQSIGSWLAWYQQKPGKAPKLL IYKASSLESVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQQYELYSY

	SFDPWGQGTLVTVSS (SEQ ID NO:37)	TFGGGTKVEIK (SEQ ID NO:38)
ADI-29447 (F47)	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPWGQGTLVTVSS (SEQ ID NO:39)	DIQMTQSPSTLSASVGDRVITICR ASQSISSWLAWYQQKPGKAPKLL IYKASSLESQVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQQYDTFIT FGGGGTKVEIK (SEQ ID NO:40)
ADI-27727	QVQLVQSGAEVKKPGSSVKVSCKAS GGTFSSYAISWVRQAPGQGLEWMGG IIPFGTANYAQKFQGRVTITADEST TAYMELSSLRSEDVAVYYCARGDSSI RHAYYYYGMDVWGQGTITVTVSS (SEQ ID NO:41) CDR1 (SEQ ID NO:57) – GTFSSYAIS CDR2 (SEQ ID NO:58) – GIIPFGTANYAQKFQG CDR3 (SEQ ID NO:59) – ARGDSSIRHAYYYYGMDV	DIVMTQSPDSLAVSLGERATINCK SSQSVLYSSNNKNYLAWYQQKP GQPPKLLIYWASTRESGVDPDRFSG SGSGTDFTLTISSLQAEDVAVYYC QQYYSTPITFGGGGTKVEIK (SEQ ID NO:42) CDR1 (SEQ ID NO:60) – KSSQSVLYSSNNKNYLA CDR2 (SEQ ID NO:61) – WASTRES CDR3 (SEQ ID NO:62) – QQYYSTPIT
ADI-29443 (F43)	QLQLQESGPGLVKPSETLSLTCTVSG GSISSSSYWGWRQPPGKGLEWIGSI YYSGSTYYNPSLKSRTISVDTSKNQ FSLKLSSVTAADTAVYYCARGSDRF HPYFDYWGQGTITVTVSS (SEQ ID NO:43) CDR1 (SEQ ID NO:63) – GSISSSSYWG CDR2 (SEQ ID NO:64) – SIYYSGSTYYNPSLKS CDR3 (SEQ ID NO:65) – ARGSDRFHPYFDY	EIVLTQSPATLSLSPGERATLSCRA SQSVSRYLAWYQQKPGQAPRLLI YDASNRTGIPARFSGSGSGTDFTL LTISSLEPEDFAVYYCQQFDTWPP TFGGGTKVEIK (SEQ ID NO:44) CDR1 (SEQ ID NO:66) – RASQSVSRYLA CDR2 (SEQ ID NO:67) – DASNRT CDR3 (SEQ ID NO:68) – QQFDTWPPT

ADI-29404 (F04)	QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYYWSWIRQPPGKGLEWIGEI DHSGSTNYNPSLKSRTISVDTSKNQ FSLKLSSVTAADTAVYYCARARGPW SFDPWGQGTTLTVVSS (SEQ ID NO:45)	DIQMTQSPSTLSASVGDRVITICR ASQSISSWLAWYQQKPGKAPKLL IYKASSLESGVPSRFSGSGSGTEFT LTISSLQPDDFATYYCEQYDSYPT FGGGTKVEIK (SEQ ID NO:46)
ADI-28200	QVQLVQSGAEVKKPGSSVKVCKAS GGTFSSYAIWVRQAPGQGLEWMGG IIPFGTANYAQKFQGRVTITADESTS TAYMELSSLRSEDVAVYYCARRGRK ASGSFYFYYGMDVWGQGTTLTVVSS (SEQ ID NO:47)	DIVMTQSPDSLAVSLGERATINCE SSQSLLNSGNQKNYLTWYQQKP GQPPKPLIWASTRESGVPRFSG SGSGTDFTLTISSLQAEDVAVYYC QNDYSYPYTFGQGTKLEIK (SEQ ID NO:48)
ADI-27744 (A44)	EVQLLESGGGLVQPGGSLRLSCAASG FTFSSYAMSWVRQAPGKGLEWVSAI SGSGGSTYYADSVKGRFTISRDN SKN TLYLQMNSLRAEDTAVYYCAKDGG YYDSGAGDYWGQGTTLTVVSS (SEQ ID NO:69) CDR1 (SEQ ID NO:71) - FTFSSYAMS CDR2 (SEQ ID NO:72) - AISGSGGSTYYADSVKG CDR3 (SEQ ID NO:73) - AKDGGYYDSGAGDY	DIQMTQSPSSVSASVGDRVITICR ASQGIDSWLAWYQQKPGKAPKL LIYAASSLQSGVPSRFSGSGSGTD FTLTISSLQPEDFATYYCQQGVSY PRTFGGGTKVEIK (SEQ ID NO:70) CDR1 (SEQ ID NO:74) - RASQGIDSWLA CDR2 (SEQ ID NO:75) - AASSLQS CDR3 (SEQ ID NO:76) - QQGVSYPR
ADI-27749 (A49)	EVQLVESGGGLVKPGGSLRLSCAAS GFTFSSYSMNWVRQAPGKGLEWVSS ISSSSSYIYYADSVKGRFTISRDN AKN SLYLQMNSLRAEDTAVYYCARGAP MGAAAGWFDPWGQGTTLTVVSS (SEQ ID NO:77) CDR1 (SEQ ID NO:79) - FTFSSYSMN CDR2 (SEQ ID NO:80) - SISSSSSYIYYADSVKG	DIQMTQSPSSVSASVGDRVITICR ASQGISSWLAWYQQKPGKAPKLL IYAASSLQSGVPSRFSGSGSGTDF TLTISSLQPEDFATYYCQQGVSP RTFGGGTKVEIK (SEQ ID NO:78) CDR1 (SEQ ID NO:82) - RASQGISSWLA CDR2 (SEQ ID NO:83) - AASSLQS

	CDR3 (SEQ ID NO:81) - ARGAPMGAAAGWFDP	CDR3 (SEQ ID NO:84) - QQGVSPRT
ADI-29463 (F63)	QVQLVQSGAEVKKPGASVKVSCAS GYTFTGYMHWRQAPGQGLEWM GWINPNSGGTNYAQKFQGRVTMTR DTSISTAYMELSLRSDDTAVYYCAR DTGEYYDTDDHGMDVWGQGTTVTV SS (SEQ ID NO:85) CDR1 (SEQ ID NO:87) - YTFTGYMH CDR2 (SEQ ID NO:88) - WINPNSGGTNYAQKFQG CDR3 (SEQ ID NO:89) - ARDTGEYYDTDDHGMDV	EIVLTQSPGTLSPGERATLSCRA SQSVSSNLAWYQQKPGQAPRLLI YGASTRATGIPARFSGSGSGTEFT LTISSLQSEDFAVYYCQQDDYWP PTFGGGTKVEIK (SEQ ID NO:86) CDR1 (SEQ ID NO:90) - RASQSVSSNLA CDR2 (SEQ ID NO:91) - GASTRAT CDR3 (SEQ ID NO:92) - QQDDYWPPT
ADI-29379 (E79)	QVQLVQSGAEVKKPGASVKVSCAS GYTFTSYMHWRQAPGQGLEWM GIINPSGGSTSYAQKFQGRVTMTRDT STSTVYMELSSLRSEDVAVYYCARG APNYGDTTHDYYMDVWGKGTTVT VSS (SEQ ID NO:133) CDR1 (SEQ ID NO:135) - YTFTSYMH CDR2 (SEQ ID NO:136) - IINPSGGSTSYAQKFQG CDR3 (SEQ ID NO:137) - ARGAPNYGDTTHDYYMDV	EIVMTQSPATLSVSPGERATLSCR ASQSVSSNLAWYQQKPGQAPRLI IYGASTRATGIPARFSGSGSGTEFT LTISSLQSEDFAVYYCQQYDDWP FTFGGGTKVEIK (SEQ ID NO:134) CDR1 (SEQ ID NO:138) - RASQSVSSNLA CDR2 (SEQ ID NO:139) - GASTRAT CDR3 (SEQ ID NO:140) - QQYDDWPPT

[00102] Alternatively, a heavy chain variable domain defined by SEQ ID NO:49 can be paired with a light chain variable domain defined by SEQ ID NO:50 to form an antigen-binding site that can bind to NKG2D, as illustrated in US 9,273,136.

QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFI
RYDGSNKYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKDRGLGDGT
YFDYWGQGTTVTVSS (SEQ ID NO:49)

5 QSALTQPASVSGSPGQSITISCSGSSSNIGNNAVNWYQQLPGKAPKLLIYDDL
LPSGVSDRFSGSKSGTSAFLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKLTVL
(SEQ ID NO:50)

[00103] Alternatively, a heavy chain variable domain defined by SEQ ID NO:51 can be paired with a light chain variable domain defined by SEQ ID NO:52 to form an antigen-binding site that can bind to NKG2D, as illustrated in US 7,879,985.

10 QVHLQESGPGLVKPSETLSLTCTVSDDISSYWWSWIRQPPGKGLEWIGHISYS
GSANYNPSLKSRTISVDTSKNQFSLKLSSVTAADTAVYYCANWDDAFNIWGQGT
MTVSS (SEQ ID NO:51)

EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASS
RATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK (SEQ
15 ID NO:52)

[00104] Table 2 lists peptide sequences of heavy chain variable domains and light chain variable domains that, in combination, can bind to CD33.

Table 2		
Clones	Heavy chain variable domain peptide sequence	Light chain variable domain peptide sequence
Lintuzumab	QVQLVQSGAEVKKPGSSVKVSCKA SGYTFTDYNMHWVRQAPGQGLEW IGYIYPYNGGTGYNQKFKSKATITA DESTNTAYMELSSLRSED TAVYYC ARGRPAMDYWGQGT LVTVSS (SEQ ID NO:93) CDR1 (SEQ ID NO:95) - GYTFTDY CDR2 (SEQ ID NO:96) - YIYPYNGGTG CDR3 (SEQ ID NO:97) - GRPAMDY	DIQMTQSPSSLSASVGDRVTITCRA SESVDNYGISFMNWFQQKPGKAP KLLIYAASNQGS GVP SRFSGSGSGT DFTLTISLQPD DFATYYCQQSKEV PWTFGQGTKVEIK (SEQ ID NO:94) CDR1(SEQ ID NO:98) - ESVDNYGISFMN CDR2 (SEQ ID NO:99) - AASNQGS CDR3 (SEQ ID NO:100) -

		QQSKEVPWT
Gemtuzumab	EVQLVQSGAEVKKPGSSVKVSCKA SGYTITDSNIHWVRQAPGQSLEWIG YIYPYNGGTDYNQKFKNRATLTVD NPTNTAYMELSSLRSEDFAFYICV NGNPWLAYWGQGTLVTVSS (SEQ ID NO:101) CDR1 (SEQ ID NO:103) - GYTITDS CDR2 (SEQ ID NO:104) - YIYPYNGGTD CDR3 (SEQ ID NO:105) - GNPWLAY	DIQLTQSPSTLSASVGDRVTITCRA SESLDNYGIRFLTWFQQKPGKAPK LLMYAASNQGSQVPSRFSGSGSGT EFTLTISLQPDFFATYYCQQTKEV PWSFGQGTKVEVK (SEQ ID NO:102) CDR1 (SEQ ID NO:106) - ESLDNYGIRFLT CDR2 (SEQ ID NO:107) - AASNQGS CDR3 (SEQ ID NO:108) - QQTKEVPWS
anti-CD33 (US 7,557,189)	QVQLQQPGAIEVVKPGASVKMSCK ASGYTFTSYIHWIKTPGQGLEW VGVYIPGNDDISYNQKFGKATLT ADKSSTTAYMQLSSLTSEDSAVYY CAREVRLRYFDVWGQGTTVTVSS (SEQ ID NO:109) CDR1 (SEQ ID NO:111) - GYTFTSY CDR2 (SEQ ID NO:112) - YPGNDD CDR3 (SEQ ID NO:113) - EVRLRYFDV	EIVLTQSPGSLAVSPGERVTMSCKS SQSVFFSSSQKNYLAWYQQIPGQS PRLLIYWASTRESGVPDRFTGSGS GTDFTLTISLVQPEDLAIIYCHQYL SSRTFGQGTKLEIKR (SEQ ID NO:110) CDR1 (SEQ ID NO:114) - QSVFFSSSQKNYLA CDR2 (SEQ ID NO:115) - WASTRES CDR3 (SEQ ID NO:116) - HQYLSSRT
vadastuximab (US 13/804,227)	QVQLVQSGAEVKKPGASVKVSCK ASGYTFTNYDINWVRQAPGQGLE WIGWIYPGDGSTKYNEKFKAKATL TADTSTSTAYMELRSLRSDDTAVY YCASGYEDAMDYWGQGTTVTVSS A (SEQ ID NO:117) CDR1 (SEQ ID NO:119): GYTFTNY	DIQMTQSPSSLSASVGDRVTINCK ASQDINSYLSWFQQKPGKAPKTLI YRANRLVDGVPSRFSGSGSGQDYT LTISSLQPEDFATYYCLQYDEFPLT FGGGTKVEIKR (SEQ ID NO:118) CDR1 (SEQ ID NO:122): QDINSYLS CDR2 (SEQ ID NO:123): RANRLVD

	CDR2 (SEQ ID NO:120): YPGDGS CDR3 (SEQ ID NO:121): GYEDAMDY	CDR3 (SEQ ID NO:124): LQYDEFPLT
--	---	------------------------------------

[00105] Alternatively, novel antigen-binding sites that can bind to CD33 can be identified by screening for binding to the amino acid sequence defined by SEQ ID NO:53.

SEQ ID NO:53

5 MPLLLLLPLLWAGALAMDPNFWLQVQESVTVQEGLCVLVPCTFFHPIPYDKNSPV
HGYWFREGAIISRDSPVATNKLDQEVQEETQGRFRLLGDPNRNCSLSIVDARRRDN
GSYFFRMERGSTKYSYKSPQLSVHVTDLTHRPKILIPGTLEPGHSKNLTCVSWACEQ
GTPPIFSWLSAAPTSLGPRTHSSVLIITPRPQDHGTNLTCQVKFAGAGVTTERTIQLN
VTYVPQNPTTGIFPGDGSQKQETRAGVVHGAIGGAGVTALLALCLCLIFFIVKTHRRK
10 AARTAVGRNDTHPTTGSASPKHQKSKLHGPTETSSCSGAAPTVMDEELHYASLN
FHGMNPSKDTSTEYSEVRTQ

[00106] Within the Fc domain, CD16 binding is mediated by the hinge region and the CH2 domain. For example, within human IgG1, the interaction with CD16 is primarily focused on amino acid residues Asp 265 – Glu 269, Asn 297 – Thr 299, Ala 327 – Ile 332, Leu 234 – Ser 239, and carbohydrate residue N-acetyl-D-glucosamine in the CH2 domain (*see*, Sonderrmann *et al*, Nature, 406 (6793):267-273). Based on the known domains, mutations can be selected to enhance or reduce the binding affinity to CD16, such as by using phage-displayed libraries or yeast surface-displayed cDNA libraries, or can be designed based on the known three-dimensional structure of the interaction.

20 **[00107]** The assembly of heterodimeric antibody heavy chains can be accomplished by expressing two different antibody heavy chain sequences in the same cell, which may lead to the assembly of homodimers of each antibody heavy chain as well as assembly of heterodimers. Promoting the preferential assembly of heterodimers can be accomplished by incorporating different mutations in the CH3 domain of each antibody heavy chain constant
25 region as shown in US13/494870, US16/028850, US11/533709, US12/875015, US13/289934, US14/773418, US12/811207, US13/866756, US14/647480, and US14/830336. For example, mutations can be made in the CH3 domain based on human IgG1 and incorporating distinct pairs of amino acid substitutions within a first polypeptide and a second polypeptide that allow these two chains to selectively heterodimerize with each
30 other. The positions of amino acid substitutions illustrated below are all numbered according to the EU index as in Kabat.

[00108] In one scenario, an amino acid substitution in the first polypeptide replaces the original amino acid with a larger amino acid, selected from arginine (R), phenylalanine (F), tyrosine (Y) or tryptophan (W), and at least one amino acid substitution in the second polypeptide replaces the original amino acid(s) with a smaller amino acid(s), chosen from alanine (A), serine (S), threonine (T), or valine (V), such that the larger amino acid substitution (a protuberance) fits into the surface of the smaller amino acid substitutions (a cavity). For example, one polypeptide can incorporate a T366W substitution, and the other can incorporate three substitutions including T366S, L368A, and Y407V.

[00109] An antibody heavy chain variable domain of the invention can optionally be coupled to an amino acid sequence at least 90% identical to an antibody constant region, such as an IgG constant region including hinge, CH2 and CH3 domains with or without CH1 domain. In some embodiments, the amino acid sequence of the constant region is at least 90% identical to a human antibody constant region, such as a human IgG1 constant region, an IgG2 constant region, IgG3 constant region, or IgG4 constant region. In some other embodiments, the amino acid sequence of the constant region is at least 90% identical to an antibody constant region from another mammal, such as rabbit, dog, cat, mouse, or horse. One or more mutations can be incorporated into the constant region as compared to human IgG1 constant region, for example at Q347, Y349, L351, S354, E356, E357, K360, Q362, S364, T366, L368, K370, N390, K392, T394, D399, S400, D401, F405, Y407, K409, T411 and/or K439. Exemplary substitutions include, for example, Q347E, Q347R, Y349S, Y349K, Y349T, Y349D, Y349E, Y349C, T350V, L351K, L351D, L351Y, S354C, E356K, E357Q, E357L, E357W, K360E, K360W, Q362E, S364K, S364E, S364H, S364D, T366V, T366I, T366L, T366M, T366K, T366W, T366S, L368E, L368A, L368D, K370S, N390D, N390E, K392L, K392M, K392V, K392F, K392D, K392E, T394F, T394W, D399R, D399K, D399V, S400K, S400R, D401K, F405A, F405T, Y407A, Y407I, Y407V, K409F, K409W, K409D, T411D, T411E, K439D, and K439E.

[00110] In certain embodiments, mutations that can be incorporated into the CH1 of a human IgG1 constant region may be at amino acid V125, F126, P127, T135, T139, A140, F170, P171, and/or V173. In certain embodiments, mutations that can be incorporated into the C κ of a human IgG1 constant region may be at amino acid E123, F116, S176, V163, S174, and/or T164.

[00111] Amino acid substitutions could be selected from the following sets of substitutions shown in Table 3.

Table 3		
	First Polypeptide	Second Polypeptide
Set 1	S364E/F405A	Y349K/T394F
Set 2	S364H/D401K	Y349T/T411E
Set 3	S364H/T394F	Y349T/F405A
Set 4	S364E/T394F	Y349K/F405A
Set 5	S364E/T411E	Y349K/D401K
Set 6	S364D/T394F	Y349K/F405A
Set 7	S364H/F405A	Y349T/T394F
Set 8	S364K/E357Q	L368D/K370S
Set 9	L368D/K370S	S364K
Set 10	L368E/K370S	S364K
Set 11	K360E/Q362E	D401K
Set 12	L368D/K370S	S364K/E357L
Set 13	K370S	S364K/E357Q
Set 14	F405L	K409R
Set 15	K409R	F405L

[00112] Alternatively, amino acid substitutions could be selected from the following sets of substitutions shown in Table 4.

Table 4		
	First Polypeptide	Second Polypeptide
Set 1	K409W	D399V/F405T
Set 2	Y349S	E357W
Set 3	K360E	Q347R
Set 4	K360E/K409W	Q347R/D399V/F405T
Set 5	Q347E/K360E/K409W	Q347R/D399V/F405T
Set 6	Y349S/K409W	E357W/D399V/F405T

[00113] Alternatively, amino acid substitutions could be selected from the following set of substitutions shown in Table 5.

5

Table 5		
	First Polypeptide	Second Polypeptide
Set 1	T366K/L351K	L351D/L368E
Set 2	T366K/L351K	L351D/Y349E
Set 3	T366K/L351K	L351D/Y349D
Set 4	T366K/L351K	L351D/Y349E/L368E
Set 5	T366K/L351K	L351D/Y349D/L368E
Set 6	E356K/D399K	K392D/K409D

[00114] Alternatively, at least one amino acid substitution in each polypeptide chain could be selected from Table 6.

Table 6	
First Polypeptide	Second Polypeptide
L351Y, D399R, D399K, S400K, S400R, Y407A, Y407I, Y407V	T366V, T366I, T366L, T366M, N390D, N390E, K392L, K392M, K392V, K392F, K392D, K392E, K409F, K409W, T411D and T411E

- [00115]** Alternatively, at least one amino acid substitutions could be selected from the following set of substitutions in Table 7, where the position(s) indicated in the First Polypeptide column is replaced by any known negatively-charged amino acid, and the position(s) indicated in the Second Polypeptide Column is replaced by any known positively-charged amino acid.

Table 7	
First Polypeptide	Second Polypeptide
K392, K370, K409, or K439	D399, E356, or E357

- [00116]** Alternatively, at least one amino acid substitutions could be selected from the following set of in Table 8, where the position(s) indicated in the First Polypeptide column is replaced by any known positively-charged amino acid, and the position(s) indicated in the Second Polypeptide Column is replaced by any known negatively-charged amino acid.

Table 8	
First Polypeptide	Second Polypeptide
D399, E356, or E357	K409, K439, K370, or K392

[00117] Alternatively, amino acid substitutions could be selected from the following set in Table 9.

Table 9	
First Polypeptide	Second Polypeptide
T350V, L351Y, F405A, and Y407V	T350V, T366L, K392L, and T394W

[00118] Alternatively, or in addition, the structural stability of a heteromultimer protein may be increased by introducing S354C on either of the first or second polypeptide chain, and Y349C on the opposing polypeptide chain, which forms an artificial disulfide bridge within the interface of the two polypeptides.

[00119] The multi-specific proteins described above can be made using recombinant DNA technology well known to a skilled person in the art. For example, a first nucleic acid sequence encoding the first immunoglobulin heavy chain can be cloned into a first expression vector; a second nucleic acid sequence encoding the second immunoglobulin heavy chain can be cloned into a second expression vector; a third nucleic acid sequence encoding the immunoglobulin light chain can be cloned into a third expression vector; the first, second, and third expression vectors can be stably transfected together into host cells to produce the multimeric proteins.

[00120] To achieve the highest yield of the multi-specific protein, different ratios of the first, second, and third expression vector can be explored to determine the optimal ratio for transfection into the host cells. After transfection, single clones can be isolated for cell bank generation using methods known in the art, such as limited dilution, ELISA, FACS, microscopy, or Clonepix.

[00121] Clones can be cultured under conditions suitable for bio-reactor scale-up and maintained expression of the multi-specific protein. The multi-specific proteins can be isolated and purified using methods known in the art including centrifugation, depth filtration, cell lysis, homogenization, freeze-thawing, affinity purification, gel filtration, ion exchange chromatography, hydrophobic interaction exchange chromatography, and mixed-mode chromatography.

II. Characteristics of the multi-specific proteins

[00122] In certain embodiments, the multi-specific proteins described herein, which include an NKG2D-binding domain and a binding domain for CD33, bind to cells expressing human NKG2D. In certain embodiments, the multi-specific proteins bind to the tumor associated antigen CD33 at a comparable level to that of a monoclonal antibody having the same CD33-binding domain. However, the multi-specific proteins described herein can be more effective in reducing tumor growth and killing cancer cells expressing CD33 than the corresponding CD33 monoclonal antibodies.

[00123] In certain embodiments, the multi-specific proteins described herein, which include an NKG2D-binding domain and a binding domain for CD33, can activate primary human NK cells when culturing with tumor cells expressing the antigen CD33. NK cell activation is marked by the increase in CD107a degranulation and IFN γ cytokine production. Furthermore, compared to a monoclonal antibody that includes the same CD33-binding domain, the multi-specific proteins show superior activation of human NK cells in the presence of tumor cells expressing the antigen CD33.

[00124] In certain embodiments, the multi-specific proteins described herein, which include an NKG2D-binding domain and a binding domain for CD33, can enhance the activity of rested and IL-2-activated human NK cells in the presence of tumor cells expressing the antigen CD33.

[00125] In certain embodiments, the multi-specific proteins described herein, which include an NKG2D-binding domain and a binding domain for a tumor associated antigen CD33, can enhance the cytotoxic activity of rested and IL-2-activated human NK cells in the presence of tumor cells expressing the antigen CD33. In certain embodiments, compared to the corresponding monoclonal antibodies, the multi-specific proteins can offer an advantage against tumor cells expressing medium and low CD33.

[00126] In certain embodiments, the multi-specific proteins described herein can be advantageous in treating cancers with high expression of Fc receptor (FcR), or cancers residing in a tumor microenvironment with high levels of FcR, compared to the corresponding CD33 monoclonal antibodies. Monoclonal antibodies exert their effects on tumor growth through multiple mechanisms including ADCC, CDC, phagocytosis, and signal blockade amongst others. Amongst Fc γ Rs, CD16 has the lowest affinity for IgG Fc; Fc γ RI (CD64) is the high-affinity FcR, which binds about 1000 times more strongly to IgG Fc than CD16. CD64 is normally expressed on many hematopoietic lineages such as the myeloid lineage, and can be expressed on tumors derived from these cell types, such as acute myeloid

leukemia (AML). Immune cells infiltrating into the tumor, such as MDSCs and monocytes, also express CD64 and are known to infiltrate the tumor microenvironment. Expression of CD64 by the tumor or in the tumor microenvironment can have a detrimental effect on monoclonal antibody therapy. Expression of CD64 in the tumor microenvironment makes it difficult for these antibodies to engage CD16 on the surface of NK cells, as the antibodies prefer to bind the high-affinity receptor. The multi-specific proteins, through targeting two activating receptors on the surface of NK cells, can overcome the detrimental effect of CD64 expression (either on tumor or tumor microenvironment) on monoclonal antibody therapy. Regardless of CD64 expression on the tumor cells, the multi-specific proteins are able to mediate human NK cell responses against all tumor cells, because dual targeting of two activating receptors on NK cells provides stronger specific binding to NK cells.

[00127] In some embodiments, the multi-specific proteins described herein can provide a better safety profile through reduced on-target off-tumor side effects. Natural killer cells and CD8 T cells are both able to directly lyse tumor cells, although the mechanisms through which NK cells and CD8 T cell recognize normal self from tumor cells differ. The activity of NK cells is regulated by the balance of signals from activating (NCRs, NKG2D, CD16, *etc.*) and inhibitory (KIRs, NKG2A, *etc.*) receptors. The balance of these activating and inhibitory signals allow NK cells to determine healthy self-cells from stressed, virally infected, or transformed self-cells. This “built-in” mechanism of self-tolerance will help protect normal healthy tissue from NK cell responses. To extend this principle, the self-tolerance of NK cells will allow TriNKETs to target antigens expressed both on self and tumor without off tumor side effects, or with an increased therapeutic window. Unlike natural killer cells, T cells require recognition of a specific peptide presented by MHC molecules for activation and effector functions. T cells have been the primary target of immunotherapy, and many strategies have been developed to redirect T cell responses against the tumor. T cell bispecifics, checkpoint inhibitors, and CAR-T cells have all been approved by the FDA, but often suffer from dose-limiting toxicities. T cell bispecifics and CAR-T cells work around the TCR-MHC recognition system by using binding domains to target antigens on the surface of tumor cells, and using engineered signaling domains to transduce the activation signals into the effector cell. Although effective at eliciting an anti-tumor immune response these therapies are often coupled with cytokine release syndrome (CRS), and on-target off-tumor side effects. The multi-specific proteins are unique in this context as they will not “override” the natural systems of NK cell activation and inhibition. Instead, the multi-specific proteins

are designed to sway the balance, and provide additional activation signals to the NK cells, while maintaining NK tolerance to healthy self.

[00128] In some embodiments, the multi-specific proteins described herein can delay progression of the tumor more effectively than the corresponding CD33 monoclonal antibodies that include the same CD33-binding domain. In some embodiments, the multi-specific proteins described herein can be more effective against cancer metastases than the corresponding CD33 monoclonal antibodies that include the same CD33-binding domain.

III. THERAPEUTIC APPLICATIONS

[00129] The invention provides methods for treating cancer using a multi-specific binding protein described herein and/or a pharmaceutical composition described herein. The methods may be used to treat a variety of cancers which express CD33 by administering to a patient in need thereof a therapeutically effective amount of a multi-specific binding protein described herein.

[00130] The therapeutic method can be characterized according to the cancer to be treated. For example, in certain embodiments, the cancer is AML, myelodysplastic syndromes, chronic myelomonocytic leukemia, myeloid blast crisis of chronic myeloid leukemia, and ALLs.

[00131] In certain other embodiments, the cancer is brain cancer, breast cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, leukemia, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, rectal cancer, renal cancer, stomach cancer, testicular cancer, or uterine cancer. In yet other embodiments, the cancer is a squamous cell carcinoma, adenocarcinoma, small cell carcinoma, melanoma, neuroblastoma, sarcoma (*e.g.*, an angiosarcoma or chondrosarcoma), larynx cancer, parotid cancer, biliary tract cancer, thyroid cancer, acral lentiginous melanoma, actinic keratoses, acute lymphocytic leukemia, acute myeloid leukemia, adenoid cystic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, anal canal cancer, anal cancer, anorectum cancer, astrocytic tumor, bartholin gland carcinoma, basal cell carcinoma, biliary cancer, bone cancer, bone marrow cancer, bronchial cancer, bronchial gland carcinoma, carcinoid, cholangiocarcinoma, chondrosarcoma, choroid plexus papilloma/carcinoma, chronic lymphocytic leukemia, chronic myeloid leukemia, clear cell carcinoma, connective tissue cancer, cystadenoma, digestive system cancer, duodenum cancer, endocrine system cancer, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, endothelial cell cancer, ependymal cancer, epithelial cell

cancer, Ewing's sarcoma, eye and orbit cancer, female genital cancer, focal nodular hyperplasia, gallbladder cancer, gastric antrum cancer, gastric fundus cancer, gastrinoma, glioblastoma, glucagonoma, heart cancer, hemangioblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatobiliary cancer, hepatocellular carcinoma, Hodgkin's disease, ileum cancer, insulinoma, intraepithelial neoplasia, 5 interepithelial squamous cell neoplasia, intrahepatic bile duct cancer, invasive squamous cell carcinoma, jejunum cancer, joint cancer, Kaposi's sarcoma, pelvic cancer, large cell carcinoma, large intestine cancer, leiomyosarcoma, lentigo maligna melanomas, lymphoma, male genital cancer, malignant melanoma, malignant mesothelial tumors, medulloblastoma, 10 medulloepithelioma, meningeal cancer, mesothelial cancer, metastatic carcinoma, mouth cancer, mucoepidermoid carcinoma, multiple myeloma, muscle cancer, nasal tract cancer, nervous system cancer, neuroepithelial adenocarcinoma nodular melanoma, non-epithelial skin cancer, non-Hodgkin's lymphoma, oat cell carcinoma, oligodendroglial cancer, oral cavity cancer, osteosarcoma, papillary serous adenocarcinoma, penile cancer, pharynx cancer, 15 pituitary tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma, rectal cancer, renal cell carcinoma, respiratory system cancer, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, sinus cancer, skin cancer, small cell carcinoma, small intestine cancer, smooth muscle cancer, soft tissue cancer, somatostatin-secreting tumor, spine cancer, squamous cell carcinoma, striated muscle cancer, submesothelial cancer, superficial 20 spreading melanoma, T cell leukemia, tongue cancer, undifferentiated carcinoma, ureter cancer, urethra cancer, urinary bladder cancer, urinary system cancer, uterine cervix cancer, uterine corpus cancer, uveal melanoma, vaginal cancer, verrucous carcinoma, VIPoma, vulva cancer, well differentiated carcinoma, or Wilms tumor.

[00132] In certain other embodiments, the cancer is non-Hodgkin's lymphoma, such as a 25 B-cell lymphoma or a T-cell lymphoma. In certain embodiments, the non-Hodgkin's lymphoma is a B-cell lymphoma, such as a diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone B-cell lymphoma, extranodal marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, Burkitt 30 lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, or primary central nervous system (CNS) lymphoma. In certain other embodiments, the non-Hodgkin's lymphoma is a T-cell lymphoma, such as a precursor T-lymphoblastic lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, angioimmunoblastic T-cell lymphoma, extranodal natural killer/T-cell lymphoma, enteropathy type T-cell lymphoma, subcutaneous

panniculitis-like T-cell lymphoma, anaplastic large cell lymphoma, or peripheral T-cell lymphoma.

[00133] The cancer to be treated can be characterized according to the presence of a particular antigen expressed on the surface of the cancer cell. In certain embodiments, the cancer cell can express one or more of the following in addition to CD33: CD2, CD19, CD20, CD30, CD38, CD40, CD52, CD70, EGFR/ERBB1, IGF1R, HER3/ERBB3, HER4/ERBB4, MUC1, cMET, SLAMF7, PSCA, MICA, MICB, TRAILR1, TRAILR2, MAGE-A3, B7.1, B7.2, CTLA4, and PD1.

IV. COMBINATION THERAPY

[00134] Another aspect of the invention provides for combination therapy. Multi-specific binding proteins described herein be used in combination with additional therapeutic agents to treat the cancer.

[00135] Exemplary therapeutic agents that may be used as part of a combination therapy in treating cancer, include, for example, radiation, mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine, bicalutamide, vinorelbine, vesnarinone, aminoglutethimide, amsacrine, proglumide, elliptinium acetate, ketanserin, doxifluridine, etretinate, isotretinoin, streptozocin, nimustine, vindesine, flutamide, drogenil, butocin, carmofur, razoxane, sizofilan, carboplatin, mitolactol, tegafur, ifosfamide, prednimustine, picibanil, levamisole, teniposide, improsulfan, enocitabine, lisuride, oxymetholone, tamoxifen, progesterone, mepitiostane, epitio stanol, formestane, interferon-alpha, interferon-2 alpha, interferon-beta, interferon-gamma, colony stimulating factor-1, colony stimulating factor-2, denileukin diftitox, interleukin-2, luteinizing hormone releasing factor and variations of the aforementioned agents that may exhibit differential binding to its cognate receptor, and increased or decreased serum half-life.

[00136] An additional class of agents that may be used as part of a combination therapy in treating cancer is immune checkpoint inhibitors. Exemplary immune checkpoint inhibitors include agents that inhibit one or more of (i) cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), (ii) programmed cell death protein 1 (PD1), (iii) PDL1, (iv) LAG3, (v) B7-H3, (vi) B7-H4, and (vii) TIM3. The CTLA4 inhibitor ipilimumab has been approved by the United States Food and Drug Administration for treating melanoma.

[00137] Yet other agents that may be used as part of a combination therapy in treating cancer are monoclonal antibody agents that target non-checkpoint targets (*e.g.*, herceptin) and non-cytotoxic agents (*e.g.*, tyrosine-kinase inhibitors).

[00138] Yet other categories of anti-cancer agents include, for example: (i) an inhibitor
5 selected from an ALK Inhibitor, an ATR Inhibitor, an A2A Antagonist, a Base Excision
Repair Inhibitor, a Bcr-Abl Tyrosine Kinase Inhibitor, a Bruton's Tyrosine Kinase Inhibitor, a
CDC7 Inhibitor, a CHK1 Inhibitor, a Cyclin-Dependent Kinase Inhibitor, a DNA-PK
Inhibitor, an Inhibitor of both DNA-PK and mTOR, a DNMT1 Inhibitor, a DNMT1 Inhibitor
plus 2-chloro-deoxyadenosine, an HDAC Inhibitor, a Hedgehog Signaling Pathway Inhibitor,
10 an IDO Inhibitor, a JAK Inhibitor, a mTOR Inhibitor, a MEK Inhibitor, a MELK Inhibitor, a
MTH1 Inhibitor, a PARP Inhibitor, a Phosphoinositide 3-Kinase Inhibitor, an Inhibitor of
both PARP1 and DHODH, a Proteasome Inhibitor, a Topoisomerase-II Inhibitor, a Tyrosine
Kinase Inhibitor, a VEGFR Inhibitor, and a WEE1 Inhibitor; (ii) an agonist of OX40, CD137,
CD40, GITR, CD27, HVEM, TNFRSF25, or ICOS; and (iii) a cytokine selected from IL-12,
15 IL-15, GM-CSF, and G-CSF.

[00139] Proteins of the invention can also be used as an adjunct to surgical removal of the primary lesion.

[00140] The amount of multi-specific binding protein and additional therapeutic agent and the relative timing of administration may be selected in order to achieve a desired combined
20 therapeutic effect. For example, when administering a combination therapy to a patient in
need of such administration, the therapeutic agents in the combination, or a pharmaceutical
composition or compositions comprising the therapeutic agents, may be administered in any
order such as, for example, sequentially, concurrently, together, simultaneously and the like.
Further, for example, a multi-specific binding protein may be administered during a time
25 when the additional therapeutic agent(s) exerts its prophylactic or therapeutic effect, or *vice versa*.

V. PHARMACEUTICAL COMPOSITIONS

[00141] The present disclosure also features pharmaceutical compositions that contain a therapeutically effective amount of a protein described herein. The composition can be
30 formulated for use in a variety of drug delivery systems. One or more physiologically
acceptable excipients or carriers can also be included in the composition for proper
formulation. Suitable formulations for use in the present disclosure are found in Remington's

Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th ed., 1985. For a brief review of methods for drug delivery, see, *e.g.*, Langer (Science 249:1527-1533, 1990).

[00142] The intravenous drug delivery formulation of the present disclosure may be contained in a bag, a pen, or a syringe. In certain embodiments, the bag may be connected to a channel comprising a tube and/or a needle. In certain embodiments, the formulation may be a lyophilized formulation or a liquid formulation. In certain embodiments, the formulation may freeze-dried (lyophilized) and contained in about 12-60 vials. In certain embodiments, the formulation may be freeze-dried and 45 mg of the freeze-dried formulation may be contained in one vial. In certain embodiments, the about 40 mg – about 100 mg of freeze-dried formulation may be contained in one vial. In certain embodiments, freeze dried formulation from 12, 27, or 45 vials are combined to obtained a therapeutic dose of the protein in the intravenous drug formulation. In certain embodiments, the formulation may be a liquid formulation and stored as about 250 mg/vial to about 1000 mg/vial. In certain embodiments, the formulation may be a liquid formulation and stored as about 600 mg/vial. In certain embodiments, the formulation may be a liquid formulation and stored as about 250 mg/vial.

[00143] This present disclosure could exist in a liquid aqueous pharmaceutical formulation including a therapeutically effective amount of the protein in a buffered solution forming a formulation.

[00144] These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as-is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the preparations typically will be between 3 and 11, more preferably between 5 and 9 or between 6 and 8, and most preferably between 7 and 8, such as 7 to 7.5. The resulting compositions in solid form may be packaged in multiple single dose units, each containing a fixed amount of the above-mentioned agent or agents. The composition in solid form can also be packaged in a container for a flexible quantity.

[00145] In certain embodiments, the present disclosure provides a formulation with an extended shelf life including the protein of the present disclosure, in combination with mannitol, citric acid monohydrate, sodium citrate, disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, polysorbate 80, water, and sodium hydroxide.

[00146] In certain embodiments, an aqueous formulation is prepared including the protein of the present disclosure in a pH-buffered solution. The buffer of this invention may have a

pH ranging from about 4 to about 8, *e.g.*, from about 4.5 to about 6.0, or from about 4.8 to about 5.5, or may have a pH of about 5.0 to about 5.2. Ranges intermediate to the above recited pH's are also intended to be part of this disclosure. For example, ranges of values using a combination of any of the above recited values as upper and/or lower limits are intended to be included. Examples of buffers that will control the pH within this range include acetate (*e.g.* sodium acetate), succinate (such as sodium succinate), gluconate, histidine, citrate and other organic acid buffers.

[00147] In certain embodiments, the formulation includes a buffer system which contains citrate and phosphate to maintain the pH in a range of about 4 to about 8. In certain embodiments the pH range may be from about 4.5 to about 6.0, or from about pH 4.8 to about 5.5, or in a pH range of about 5.0 to about 5.2. In certain embodiments, the buffer system includes citric acid monohydrate, sodium citrate, disodium phosphate dihydrate, and/or sodium dihydrogen phosphate dihydrate. In certain embodiments, the buffer system includes about 1.3 mg/ml of citric acid (*e.g.*, 1.305 mg/ml), about 0.3 mg/ml of sodium citrate (*e.g.*, 0.305 mg/ml), about 1.5 mg/ml of disodium phosphate dihydrate (*e.g.*, 1.53 mg/ml), about 0.9 mg/ml of sodium dihydrogen phosphate dihydrate (*e.g.*, 0.86), and about 6.2 mg/ml of sodium chloride (*e.g.*, 6.165 mg/ml). In certain embodiments, the buffer system includes 1-1.5 mg/ml of citric acid, 0.25 to 0.5 mg/ml of sodium citrate, 1.25 to 1.75 mg/ml of disodium phosphate dihydrate, 0.7 to 1.1 mg/ml of sodium dihydrogen phosphate dihydrate, and 6.0 to 6.4 mg/ml of sodium chloride. In certain embodiments, the pH of the formulation is adjusted with sodium hydroxide.

[00148] A polyol, which acts as a tonicifier and may stabilize the antibody, may also be included in the formulation. The polyol is added to the formulation in an amount which may vary with respect to the desired isotonicity of the formulation. In certain embodiments, the aqueous formulation may be isotonic. The amount of polyol added may also be altered with respect to the molecular weight of the polyol. For example, a lower amount of a monosaccharide (*e.g.*, mannitol) may be added, compared to a disaccharide (such as trehalose). In certain embodiments, the polyol which may be used in the formulation as a tonicity agent is mannitol. In certain embodiments, the mannitol concentration may be about 5 to about 20 mg/ml. In certain embodiments, the concentration of mannitol may be about 7.5 to 15 mg/ml. In certain embodiments, the concentration of mannitol may be about 10-14 mg/ml. In certain embodiments, the concentration of mannitol may be about 12 mg/ml. In certain embodiments, the polyol sorbitol may be included in the formulation.

[00149] A detergent or surfactant may also be added to the formulation. Exemplary detergents include nonionic detergents such as polysorbates (*e.g.*, polysorbates 20, 80 etc.) or poloxamers (*e.g.*, poloxamer 188). The amount of detergent added is such that it reduces aggregation of the formulated antibody and/or minimizes the formation of particulates in the formulation and/or reduces adsorption. In certain embodiments, the formulation may include a surfactant which is a polysorbate. In certain embodiments, the formulation may contain the detergent polysorbate 80 or Tween 80. Tween 80 is a term used to describe polyoxyethylene (20) sorbitanmonooleate (see Fiedler, Lexikon der Hilfsstoffe, Editio Cantor Verlag Aulendorf, 4th edi., 1996). In certain embodiments, the formulation may contain between about 0.1 mg/mL and about 10 mg/mL of polysorbate 80, or between about 0.5 mg/mL and about 5 mg/mL. In certain embodiments, about 0.1% polysorbate 80 may be added in the formulation.

[00150] In embodiments, the protein product of the present disclosure is formulated as a liquid formulation. The liquid formulation may be presented at a 10 mg/mL concentration in either a USP / Ph Eur type I 50R vial closed with a rubber stopper and sealed with an aluminum crimp seal closure. The stopper may be made of elastomer complying with USP and Ph Eur. In certain embodiments vials may be filled with 61.2 mL of the protein product solution in order to allow an extractable volume of 60 mL. In certain embodiments, the liquid formulation may be diluted with 0.9% saline solution.

[00151] In certain embodiments, the liquid formulation of the disclosure may be prepared as a 10 mg/mL concentration solution in combination with a sugar at stabilizing levels. In certain embodiments the liquid formulation may be prepared in an aqueous carrier. In certain embodiments, a stabilizer may be added in an amount no greater than that which may result in a viscosity undesirable or unsuitable for intravenous administration. In certain embodiments, the sugar may be disaccharides, *e.g.*, sucrose. In certain embodiments, the liquid formulation may also include one or more of a buffering agent, a surfactant, and a preservative.

[00152] In certain embodiments, the pH of the liquid formulation may be set by addition of a pharmaceutically acceptable acid and/or base. In certain embodiments, the pharmaceutically acceptable acid may be hydrochloric acid. In certain embodiments, the base may be sodium hydroxide.

[00153] In addition to aggregation, deamidation is a common product variant of peptides and proteins that may occur during fermentation, harvest/cell clarification, purification, drug substance/drug product storage and during sample analysis. Deamidation is the loss of NH₃

from a protein forming a succinimide intermediate that can undergo hydrolysis. The succinimide intermediate results in a 17 dalton mass decrease of the parent peptide. The subsequent hydrolysis results in an 18 dalton mass increase. Isolation of the succinimide intermediate is difficult due to instability under aqueous conditions. As such, deamidation is typically detectable as 1 dalton mass increase. Deamidation of an asparagine results in either aspartic or isoaspartic acid. The parameters affecting the rate of deamidation include pH, temperature, solvent dielectric constant, ionic strength, primary sequence, local polypeptide conformation and tertiary structure. The amino acid residues adjacent to Asn in the peptide chain affect deamidation rates. Gly and Ser following an Asn in protein sequences results in a higher susceptibility to deamidation.

[00154] In certain embodiments, the liquid formulation of the present disclosure may be preserved under conditions of pH and humidity to prevent deamination of the protein product.

[00155] The aqueous carrier of interest herein is one which is pharmaceutically acceptable (safe and non-toxic for administration to a human) and is useful for the preparation of a liquid formulation. Illustrative carriers include sterile water for injection (SWFI), bacteriostatic water for injection (BWFI), a pH buffered solution (*e.g.*, phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose solution.

[00156] A preservative may be optionally added to the formulations herein to reduce bacterial action. The addition of a preservative may, for example, facilitate the production of a multi-use (multiple-dose) formulation.

[00157] Intravenous (IV) formulations may be the preferred administration route in particular instances, such as when a patient is in the hospital after transplantation receiving all drugs via the IV route. In certain embodiments, the liquid formulation is diluted with 0.9% Sodium Chloride solution before administration. In certain embodiments, the diluted drug product for injection is isotonic and suitable for administration by intravenous infusion.

[00158] In certain embodiments, a salt or buffer components may be added in an amount of 10 mM - 200 mM. The salts and/or buffers are pharmaceutically acceptable and are derived from various known acids (inorganic and organic) with "base forming" metals or amines. In certain embodiments, the buffer may be phosphate buffer. In certain embodiments, the buffer may be glycinate, carbonate, citrate buffers, in which case, sodium, potassium or ammonium ions can serve as counterion.

[00159] A preservative may be optionally added to the formulations herein to reduce bacterial action. The addition of a preservative may, for example, facilitate the production of a multi-use (multiple-dose) formulation.

[00160] The aqueous carrier of interest herein is one which is pharmaceutically acceptable (safe and non-toxic for administration to a human) and is useful for the preparation of a liquid formulation. Illustrative carriers include sterile water for injection (SWFI), bacteriostatic water for injection (BWFI), a pH buffered solution (*e.g.*, phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose solution.

[00161] This present disclosure could exist in a lyophilized formulation including the proteins and a lyoprotectant. The lyoprotectant may be sugar, *e.g.*, disaccharides. In certain embodiments, the lyoprotectant may be sucrose or maltose. The lyophilized formulation may also include one or more of a buffering agent, a surfactant, a bulking agent, and/or a preservative.

[00162] The amount of sucrose or maltose useful for stabilization of the lyophilized drug product may be in a weight ratio of at least 1:2 protein to sucrose or maltose. In certain embodiments, the protein to sucrose or maltose weight ratio may be of from 1:2 to 1:5.

[00163] In certain embodiments, the pH of the formulation, prior to lyophilization, may be set by addition of a pharmaceutically acceptable acid and/or base. In certain embodiments the pharmaceutically acceptable acid may be hydrochloric acid. In certain embodiments, the pharmaceutically acceptable base may be sodium hydroxide.

[00164] Before lyophilization, the pH of the solution containing the protein of the present disclosure may be adjusted between 6 to 8. In certain embodiments, the pH range for the lyophilized drug product may be from 7 to 8.

[00165] In certain embodiments, a salt or buffer components may be added in an amount of 10 mM - 200 mM. The salts and/or buffers are pharmaceutically acceptable and are derived from various known acids (inorganic and organic) with "base forming" metals or amines. In certain embodiments, the buffer may be phosphate buffer. In certain embodiments, the buffer may be glycinate, carbonate, citrate buffers, in which case, sodium, potassium or ammonium ions can serve as counterion.

[00166] In certain embodiments, a "bulking agent" may be added. A "bulking agent" is a compound which adds mass to a lyophilized mixture and contributes to the physical structure of the lyophilized cake (*e.g.*, facilitates the production of an essentially uniform lyophilized cake which maintains an open pore structure). Illustrative bulking agents include mannitol, glycine, polyethylene glycol and sorbitol. The lyophilized formulations of the present invention may contain such bulking agents.

[00167] A preservative may be optionally added to the formulations herein to reduce bacterial action. The addition of a preservative may, for example, facilitate the production of a multi-use (multiple-dose) formulation.

5 [00168] In certain embodiments, the lyophilized drug product may be constituted with an aqueous carrier. The aqueous carrier of interest herein is one which is pharmaceutically acceptable (*e.g.*, safe and non-toxic for administration to a human) and is useful for the preparation of a liquid formulation, after lyophilization. Illustrative diluents include sterile water for injection (SWFI), bacteriostatic water for injection (BWFI), a pH buffered solution (*e.g.*, phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose
10 solution.

[00169] In certain embodiments, the lyophilized drug product of the current disclosure is reconstituted with either Sterile Water for Injection, USP (SWFI) or 0.9% Sodium Chloride Injection, USP. During reconstitution, the lyophilized powder dissolves into a solution.

15 [00170] In certain embodiments, the lyophilized protein product of the instant disclosure is constituted to about 4.5 mL water for injection and diluted with 0.9% saline solution (sodium chloride solution).

[00171] Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and
20 mode of administration, without being toxic to the patient.

[00172] The specific dose can be a uniform dose for each patient, for example, 50-5000 mg of protein. Alternatively, a patient's dose can be tailored to the approximate body weight or surface area of the patient. Other factors in determining the appropriate dosage can include the disease or condition to be treated or prevented, the severity of the disease, the route of
25 administration, and the age, sex and medical condition of the patient. Further refinement of the calculations necessary to determine the appropriate dosage for treatment is routinely made by those skilled in the art, especially in light of the dosage information and assays disclosed herein. The dosage can also be determined through the use of known assays for determining dosages used in conjunction with appropriate dose-response data. An individual patient's
30 dosage can be adjusted as the progress of the disease is monitored. Blood levels of the targetable construct or complex in a patient can be measured to see if the dosage needs to be adjusted to reach or maintain an effective concentration. Pharmacogenomics may be used to determine which targetable constructs and/or complexes, and dosages thereof, are most likely

to be effective for a given individual (Schmitz *et al.*, *Clinica Chimica Acta* 308: 43-53, 2001; Steimer *et al.*, *Clinica Chimica Acta* 308: 33-41, 2001).

[00173] In general, dosages based on body weight are from about 0.01 µg to about 100 mg per kg of body weight, such as about 0.01 µg to about 100 mg/kg of body weight, about 0.01 µg to about 50 mg/kg of body weight, about 0.01 µg to about 10 mg/kg of body weight, about 0.01 µg to about 1 mg/kg of body weight, about 0.01 µg to about 100 µg/kg of body weight, about 0.01 µg to about 50 µg/kg of body weight, about 0.01 µg to about 10 µg/kg of body weight, about 0.01 µg to about 1 µg/kg of body weight, about 0.01 µg to about 0.1 µg/kg of body weight, about 0.1 µg to about 100 mg/kg of body weight, about 0.1 µg to about 50 mg/kg of body weight, about 0.1 µg to about 10 mg/kg of body weight, about 0.1 µg to about 1 mg/kg of body weight, about 0.1 µg to about 100 µg/kg of body weight, about 0.1 µg to about 10 µg/kg of body weight, about 0.1 µg to about 1 µg/kg of body weight, about 1 µg to about 100 mg/kg of body weight, about 1 µg to about 50 mg/kg of body weight, about 1 µg to about 10 mg/kg of body weight, about 1 µg to about 1 mg/kg of body weight, about 1 µg to about 100 µg/kg of body weight, about 1 µg to about 50 µg/kg of body weight, about 1 µg to about 10 µg/kg of body weight, about 10 µg to about 100 mg/kg of body weight, about 10 µg to about 50 mg/kg of body weight, about 10 µg to about 10 mg/kg of body weight, about 10 µg to about 1 mg/kg of body weight, about 10 µg to about 100 µg/kg of body weight, about 10 µg to about 50 µg/kg of body weight, about 50 µg to about 100 mg/kg of body weight, about 50 µg to about 50 mg/kg of body weight, about 50 µg to about 10 mg/kg of body weight, about 50 µg to about 1 mg/kg of body weight, about 50 µg to about 100 µg/kg of body weight, about 100 µg to about 100 mg/kg of body weight, about 100 µg to about 50 mg/kg of body weight, about 100 µg to about 10 mg/kg of body weight, about 100 µg to about 1 mg/kg of body weight, about 1 mg to about 100 mg/kg of body weight, about 1 mg to about 50 mg/kg of body weight, about 1 mg to about 10 mg/kg of body weight, about 10 mg to about 100 mg/kg of body weight, about 10 mg to about 50 mg/kg of body weight, about 50 mg to about 100 mg/kg of body weight.

[00174] Doses may be given once or more times daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the targetable construct or complex in bodily fluids or tissues. Administration of the present invention could be intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, intrapleural, intrathecal, intracavitary, by perfusion through a catheter or by direct intralesional injection.

This may be administered once or more times daily, once or more times weekly, once or more times monthly, and once or more times annually.

[00175] The description above describes multiple aspects and embodiments of the invention. The patent application specifically contemplates all combinations and permutations of the aspects and embodiments.

EXAMPLES

[00176] The invention now being generally described, will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and is not intended to limit the invention.

Example 1 – NKG2D-binding domains bind to NKG2D

NKG2D-binding domains bind to purified recombinant NKG2D

[00177] The nucleic acid sequences of human, mouse or cynomolgus NKG2D ectodomains were fused with nucleic acid sequences encoding human IgG1 Fc domains and introduced into mammalian cells to be expressed. After purification, NKG2D-Fc fusion proteins were adsorbed to wells of microplates. After blocking the wells with bovine serum albumin to prevent non-specific binding, NKG2D-binding domains were titrated and added to the wells pre-adsorbed with NKG2D-Fc fusion proteins. Primary antibody binding was detected using a secondary antibody which was conjugated to horseradish peroxidase and specifically recognizes a human kappa light chain to avoid Fc cross-reactivity. 3,3',5,5'-Tetramethylbenzidine (TMB), a substrate for horseradish peroxidase, was added to the wells to visualize the binding signal, whose absorbance was measured at 450 nM and corrected at 540 nM. An NKG2D-binding domain clone, an isotype control or a positive control (selected from SEQ ID NOs:45-48, or anti-mouse NKG2D clones MI-6 and CX-5 available at eBioscience) was added to each well.

[00178] The isotype control showed minimal binding to recombinant NKG2D-Fc proteins, while the positive control bound strongest to the recombinant antigens. NKG2D-binding domains produced by all clones demonstrated binding across human, mouse, and cynomolgus recombinant NKG2D-Fc proteins, although with varying affinities from clone to clone. Generally, each anti-NKG2D clone bound to human (FIG. 3) and cynomolgus (FIG. 4) recombinant NKG2D-Fc with similar affinity, but with lower affinity to mouse (FIG. 5) recombinant NKG2D-Fc.

NKG2D-binding domains bind to cells expressing NKG2D

[00179] EL4 mouse lymphoma cell lines were engineered to express human or mouse NKG2D - CD3 zeta signaling domain chimeric antigen receptors. An NKG2D-binding clone, an isotype control or a positive control was used at a 100 nM concentration to stain extracellular NKG2D expressed on the EL4 cells. The antibody binding was detected using fluorophore-conjugated anti-human IgG secondary antibodies. Cells were analyzed by flow cytometry, and fold-over-background (FOB) was calculated using the mean fluorescence intensity (MFI) of NKG2D expressing cells compared to parental EL4 cells.

[00180] NKG2D-binding domains produced by all clones bound to EL4 cells expressing human and mouse NKG2D. Positive control antibodies (selected from SEQ ID NO: 45-48, or anti-mouse NKG2D clones MI-6 and CX-5 available at eBioscience) gave the best FOB binding signal. The NKG2D-binding affinity for each clone was similar between cells expressing human NKG2D (FIG. 6) and mouse (FIG. 7) NKG2D.

Example 2 – NKG2D-binding domains block natural ligand binding to NKG2D

Competition With ULBP-6

[00181] Recombinant human NKG2D-Fc proteins were adsorbed to wells of a microplate, and the wells were blocked with bovine serum albumin to reduce non-specific binding. A saturating concentration of ULBP-6-His-biotin was added to the wells, followed by addition of the NKG2D-binding domain clones. After a 2-hour incubation, wells were washed and ULBP-6-His-biotin that remained bound to the NKG2D-Fc coated wells was detected by streptavidin-conjugated to horseradish peroxidase and TMB substrate. Absorbance was measured at 450 nM and corrected at 540 nM. After subtracting background, specific binding of NKG2D-binding domains to the NKG2D-Fc proteins was calculated from the percentage of ULBP-6-His-biotin that was blocked from binding to the NKG2D-Fc proteins in wells. The positive control antibody (selected from SEQ ID NOs:45-48) and various NKG2D-binding domains blocked ULBP-6 binding to NKG2D, while isotype control showed little competition with ULBP-6 (FIG. 8).

Competition With MICA

[00182] Recombinant human MICA-Fc proteins were adsorbed to wells of a microplate, and the wells were blocked with bovine serum albumin to reduce non-specific binding. NKG2D-Fc-biotin was added to wells followed by NKG2D-binding domains. After

incubation and washing, NKG2D-Fc-biotin that remained bound to MICA-Fc coated wells was detected using streptavidin-HRP and TMB substrate. Absorbance was measured at 450 nM and corrected at 540 nM. After subtracting background, specific binding of NKG2D-binding domains to the NKG2D-Fc proteins was calculated from the percentage of NKG2D-Fc-biotin that was blocked from binding to the MICA-Fc coated wells. The positive control antibody (selected from SEQ ID NOs:45-48) and various NKG2D-binding domains blocked MICA binding to NKG2D, while isotype control showed little competition with MICA (FIG. 9).

Competition With Rae-1 delta

- 10 [00183] Recombinant mouse Rae-1delta-Fc (purchased from R&D Systems) was adsorbed to wells of a microplate, and the wells were blocked with bovine serum albumin to reduce non-specific binding. Mouse NKG2D-Fc-biotin was added to the wells followed by NKG2D-binding domains. After incubation and washing, NKG2D-Fc-biotin that remained bound to Rae-1delta-Fc coated wells was detected using streptavidin-HRP and TMB substrate.
- 15 Absorbance was measured at 450 nM and corrected at 540 nM. After subtracting background, specific binding of NKG2D-binding domains to the NKG2D-Fc proteins was calculated from the percentage of NKG2D-Fc-biotin that was blocked from binding to the Rae-1delta-Fc coated wells. The positive control (selected from SEQ ID NOs:45-48, or anti-mouse NKG2D clones MI-6 and CX-5 available at eBioscience) and various NKG2D-binding domain clones
- 20 blocked Rae-1delta binding to mouse NKG2D, while the isotype control antibody showed little competition with Rae-1delta (FIG. 10).

Example 3 – NKG2D-binding domain clones activate NKG2D

- 25 [00184] Nucleic acid sequences of human and mouse NKG2D were fused to nucleic acid sequences encoding a CD3 zeta signaling domain to obtain chimeric antigen receptor (CAR) constructs. The NKG2D-CAR constructs were then cloned into a retrovirus vector using Gibson assembly and transfected into expi293 cells for retrovirus production. EL4 cells were infected with viruses containing NKG2D-CAR together with 8 µg/mL polybrene. 24 hours after infection, the expression levels of NKG2D-CAR in the EL4 cells were analyzed by flow
- 30 cytometry, and clones which express high levels of the NKG2D-CAR on the cell surface were selected.

[00185] To determine whether NKG2D-binding domains activate NKG2D, they were adsorbed to wells of a microplate, and NKG2D-CAR EL4 cells were cultured on the antibody fragment-coated wells for 4 hours in the presence of brefeldin-A and monensin. Intracellular

TNF-alpha production, an indicator for NKG2D activation, was assayed by flow cytometry. The percentage of TNF-alpha positive cells was normalized to the cells treated with the positive control. All NKG2D-binding domains activated both human NKG2D (FIG. 11) and mouse NKG2D (FIG. 12).

5

Example 4 – NKG2D-binding domains activate NK cells

Primary human NK cells

[00186] Peripheral blood mononuclear cells (PBMCs) were isolated from human peripheral blood buffy coats using density gradient centrifugation. NK cells (CD3⁻CD56⁺) were isolated using negative selection with magnetic beads from PBMCs, and the purity of the isolated NK cells was typically >95%. Isolated NK cells were then cultured in media containing 100 ng/mL IL-2 for 24-48 hours before they were transferred to the wells of a microplate to which the NKG2D-binding domains were adsorbed, and cultured in the media containing fluorophore-conjugated anti-CD107a antibody, brefeldin-A, and monensin. Following culture, NK cells were assayed by flow cytometry using fluorophore-conjugated antibodies against CD3, CD56 and IFN-gamma. CD107a and IFN-gamma staining were analyzed in CD3⁻CD56⁺ cells to assess NK cell activation. The increase in CD107a/IFN-gamma double-positive cells is indicative of better NK cell activation through engagement of two activating receptors rather than one receptor. NKG2D-binding domains and the positive control (selected from SEQ ID NOs:45-48) showed a higher percentage of NK cells becoming CD107a⁺ and IFN-gamma⁺ than the isotype control (FIG. 13 & FIG. 14 represent data from two independent experiments, each using a different donor's PBMC for NK cell preparation).

Primary mouse NK cells

25 [00187] Spleens were obtained from C57Bl/6 mice and crushed through a 70 µm cell strainer to obtain single cell suspension. Cells were pelleted and resuspended in ACK lysis buffer (purchased from Thermo Fisher Scientific #A1049201; 155mM ammonium chloride, 10mM potassium bicarbonate, 0.01mM EDTA) to remove red blood cells. The remaining cells were cultured with 100 ng/mL hIL-2 for 72 hours before being harvested and prepared for NK cell isolation. NK cells (CD3⁻NK1.1⁺) were then isolated from spleen cells using a negative depletion technique with magnetic beads with typically >90% purity. Purified NK cells were cultured in media containing 100 ng/mL mIL-15 for 48 hours before they were transferred to the wells of a microplate to which the NKG2D-binding domains were

adsorbed, and cultured in the media containing fluorophore-conjugated anti-CD107a antibody, brefeldin-A, and monensin. Following culture in NKG2D-binding domain-coated wells, NK cells were assayed by flow cytometry using fluorophore-conjugated antibodies against CD3, NK1.1 and IFN-gamma. CD107a and IFN-gamma staining were analyzed in CD3⁺ NK1.1⁺ cells to assess NK cell activation. The increase in CD107a/IFN-gamma double-positive cells is indicative of better NK cell activation through engagement of two activating receptors rather than one receptor. NKG2D-binding domains and the positive control (selected from anti-mouse NKG2D clones MI-6 and CX-5 available at eBioscience) showed a higher percentage of NK cells becoming CD107a⁺ and IFN-gamma⁺ than the isotype control (FIG. 15 & FIG. 16 represent data from two independent experiments, each using a different mouse for NK cell preparation).

Example 5 – NKG2D-binding domains enable cytotoxicity of target tumor cells

[00188] Human and mouse primary NK cell activation assays demonstrate increased cytotoxicity markers on NK cells after incubation with NKG2D-binding domains. To address whether this translates into increased tumor cell lysis, a cell-based assay was utilized where each NKG2D-binding domain was developed into a monospecific antibody. The Fc region was used as one targeting arm, while the Fab region (NKG2D-binding domain) acted as another targeting arm to activate NK cells. THP-1 cells, which are of human origin and express high levels of Fc receptors, were used as a tumor target and a Perkin Elmer DELFIA Cytotoxicity Kit was used. THP-1 cells were labeled with BATDA reagent, and resuspended at 10⁵/mL in culture media. Labeled THP-1 cells were then combined with NKG2D antibodies and isolated mouse NK cells in wells of a microtiter plate at 37 °C for 3 hours. After incubation, 20 µl of the culture supernatant was removed, mixed with 200 µl of Europium solution and incubated with shaking for 15 minutes in the dark. Fluorescence was measured over time by a PheraStar plate reader equipped with a time-resolved fluorescence module (Excitation 337nm, Emission 620 nm) and specific lysis was calculated according to the kit instructions.

[00189] The positive control, ULBP-6 - a natural ligand for NKG2D, showed increased specific lysis of THP-1 target cells by mouse NK cells. NKG2D antibodies also increased specific lysis of THP-1 target cells, while isotype control antibody showed reduced specific lysis. The dotted line indicates specific lysis of THP-1 cells by mouse NK cells without antibody added (FIG. 17).

Example 6 – NKG2D antibodies show high thermostability

[00190] Melting temperatures of NKG2D-binding domains were assayed using differential scanning fluorimetry. The extrapolated apparent melting temperatures are high relative to typical IgG1 antibodies (FIG. 18).

5

Example 7 - Synergistic activation of human NK cells by cross-linking NKG2D and CD16

Primary human NK cell activation assay

[00191] Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral human blood buffy coats using density gradient centrifugation. NK cells were purified from PBMCs using negative magnetic beads (StemCell # 17955). NK cells were >90% CD3⁺ CD56⁺ as determined by flow cytometry. Cells were then expanded 48 hours in media containing 100 ng/mL hIL-2 (Peprotech #200-02) before use in activation assays. Antibodies were coated onto a 96-well flat-bottom plate at a concentration of 2 µg/ml (anti-CD16, Biolegend # 302013) and 5 µg/mL (anti-NKG2D, R&D #MAB139) in 100 µl sterile PBS overnight at 4 °C followed by washing the wells thoroughly to remove excess antibody. For the assessment of degranulation IL-2-activated NK cells were resuspended at 5×10⁵ cells/ml in culture media supplemented with 100 ng/mL hIL2 and 1 µg/mL APC-conjugated anti-CD107a mAb (Biolegend # 328619). 1×10⁵ cells/well were then added onto antibody coated plates. The protein transport inhibitors Brefeldin A (BFA, Biolegend # 420601) and Monensin (Biolegend # 420701) were added at a final dilution of 1:1000 and 1:270 respectively. Plated cells were incubated for 4 hours at 37 °C in 5% CO₂. For intracellular staining of IFN-γ NK cells were labeled with anti-CD3 (Biolegend #300452) and anti-CD56 mAb (Biolegend # 318328) and subsequently fixed and permeabilized and labeled with anti-IFN-γ mAb (Biolegend # 506507). NK cells were analyzed for expression of CD107a and IFN-γ by flow cytometry after gating on live CD56⁺CD3⁺ cells.

10

15

20

25

[00192] To investigate the relative potency of receptor combination, crosslinking of NKG2D or CD16 and co-crosslinking of both receptors by plate-bound stimulation was performed. As shown in Figure 19 (FIGs. 19A-19C), combined stimulation of CD16 and NKG2D resulted in highly elevated levels of CD107a (degranulation) (FIG. 19A) and/or IFN-γ production (FIG. 19B). Dotted lines represent an additive effect of individual stimulations of each receptor.

30

[00193] CD107a levels and intracellular IFN-γ production of IL-2-activated NK cells were analyzed after 4 hours of plate-bound stimulation with anti-CD16, anti-NKG2D or a

combination of both monoclonal antibodies. Graphs indicate the mean ($n = 2$) $\pm$ SD. FIG. 19A demonstrates levels of CD107a; FIG. 19B demonstrates levels of IFN γ ; FIG. 19C demonstrates levels of CD107a and IFN γ . Data shown in FIGs. 19A-19C are representative of five independent experiments using five different healthy donors.

5 **Example 8 – Multi-specific binding proteins bind to NKG2D**

[00194] EL4 mouse lymphoma cell lines were engineered to express human NKG2D. Trispecific binding proteins (TriNKETs) that each contain an NKG2D-binding domain, a tumor-associated antigen-binding domain (CD33-binding domain), and an Fc domain that binds to CD16 as shown in FIG. 1, were tested for their affinity to extracellular NKG2D expressed on EL4 cells. The binding of the multi-specific binding proteins to NKG2D was detected using fluorophore-conjugated anti-human IgG secondary antibodies. Cells were analyzed by flow cytometry, and fold-over-background (FOB) was calculated using the mean fluorescence intensity (MFI) of NKG2D-expressing cells compared to parental EL4 cells.

[00195] TriNKETs tested include CD33-TriNKET-C26 (ADI-28226 and a CD33-binding domain), CD33-TriNKET-F04 (ADI-29404 and a CD33-binding domain), CD33-TriNKET-A44 (ADI-27744 and a CD33-binding domain), CD33-TriNKET-F47 (ADI-29447 and a CD33-binding domain), CD33-TriNKET-A49 (ADI-27749 and a CD33-binding domain) and CD33-TriNKET-F63 (ADI-27463 and a CD33-binding domain). The CD33-binding domain used in the tested molecules was composed of a heavy chain variable domain and light chain variable domain as listed below.

CD33 heavy chain variable domain (SEQ ID NO:125):

QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYVVHWRQAPGGLEWMGYINPY
CDR1 (SEQ ID NO:127) CDR2

NDGTKYNEKFKGRVTMTRDTSISTAYMELSRLSDDTAVYYCARDYRYEYVGMDY
25 (SEQ ID NO:128) CDR3 (SEQ ID NO:129)

WGQGTLLVTVSS

CD33 light chain variable domain (SEQ ID NO:126):

DIVLTQSPASLAVSPGQRATITCTASSSVNYIHWYQQKPGQPPLLIYDTSKVASGVP
30 CDR1(SEQ ID NO:130) CDR2 (SEQ ID NO:131)

ARFSGSGSGTDFTLTINPVEANDTANYYCQWRSYPLTFGQGTKLEIK

CDR3 (SEQ ID NO:132)

[00196] The data show that TriNKETs which include a CD33-binding domain and a NKG2D-binding domain bind to NKG2D (FIGs. 35A-35B). FIG. 35A shows binding of the

TriNKETs in comparison with the monoclonal antibodies which contain the corresponding NKG2D binding domain. FIG. 35B shows the binding profile of CD33-targeting TriNKETs which include 6 different NKG2D binding domains.

Example 9 – Multi-specific binding proteins bind to human tumor antigens

5 Trispecific binding proteins bind to CD33

[00197] Human AML cell line MV4-11 and Molm-13 expressing CD33 were used to assay the binding of TriNKETs to the tumor associated antigen CD33. TriNKETs and optionally the parental anti-CD33 monoclonal antibody were incubated with the cells, and the binding was detected using fluorophore-conjugated anti-human IgG secondary antibodies.

- 10 Cells were analyzed by flow cytometry, and fold-over-background (FOB) was calculated using the mean fluorescence intensity (MFI) from the TriNKETs and the parental monoclonal anti-CD33 antibody normalized to secondary antibody controls. CD33-targeting TriNKETs show comparable levels of binding to CD33 as compared with the parental anti-CD33 antibody (FIG. 36). The TriNKETs show binding to cell surface CD33 on MV4-11 (FIG. 36A, 36B, and 36D) and Molm-13 cells (FIG. 36C). The overall binding signal is
- 15 comparable among TriNKETs as they contain the same CD33 binding domain.

Example 10 – Multi-specific binding proteins activate NK cells

[00198] Peripheral blood mononuclear cells (PBMCs) were isolated from human peripheral blood buffy coats using density gradient centrifugation. NK cells (CD3⁻CD56⁺) were isolated using negative selection with magnetic beads from PBMCs, and the purity of the isolated NK cells was typically >90%. Isolated NK cells were cultured in media containing 100 ng/mL IL-2 for activation or rested overnight without cytokine. IL-2-activated NK cells were used within 24-48 hours after activation.

- 25 [00199] MV4-11 cells expressing CD33 were harvested and resuspended in culture media at 2×10^6 /mL. CD33 monoclonal antibodies or CD33-targeting TriNKETs were diluted in culture media. Activated NK cells were harvested, washed, and resuspended at 2×10^6 /mL in culture media. Cancer cells were then mixed with monoclonal antibodies/TriNKETs and activated NK cells in the presence of IL-2. Brefeldin-A and monensin were also added to the
- 30 mixed culture to block protein transport out of the cell for intracellular cytokine staining. Fluorophore-conjugated anti-CD107a was added to the mixed culture and the culture was incubated for 4 hours before samples were prepared for FACS analysis using fluorophore-

conjugated antibodies against CD3, CD56 and IFN-gamma. CD107a and IFN-gamma staining was analyzed in CD3⁺CD56⁺ cells to assess NK cell activation. The increase in CD107a/IFN-gamma double-positive cells is indicative of better NK cell activation through engagement of two activating receptors rather than one receptor.

- 5 [00200] Co-culturing primary human NK cells with CD33-positive MV4-11 cells resulted in TriNKET-mediated activation of the primary human NK cells. A CD33 targeting TriNKET mediated activation of human NK cells co-cultured with MV4-11 cells, as indicated by an increase in CD107a degranulation and IFN γ cytokine production (FIG. 37A and 37B). NK cells alone, NK cells co-culturing with MV4-11 cells but without TriNKETs, 10 CD20-targeting TriNKET were used as controls. Compared to the C33 monoclonal antibody, the CD33 targeting TriNKET showed increased NK cell activity (FIG. 37A and 37B).

Example 11 – Trispecific binding proteins enable cytotoxicity of target cancer cells

- [00201] Peripheral blood mononuclear cells (PBMCs) were isolated from human 15 peripheral blood buffy coats using density gradient centrifugation. NK cells (CD3⁺CD56⁺) were isolated using negative selection with magnetic beads from PBMCs, and the purity of the isolated NK cells was typically >90%. Isolated NK cells were cultured in media containing 100 ng/mL IL-2 for activation or rested overnight without cytokine. IL-2-activated or rested NK cells were used the following day in cytotoxicity assays.

20 DELFIA cytotoxicity assay:

- [00202] Human cancer cell lines expressing CD33 were harvested from culture, cells were washed with PBS, and were resuspended in growth media at 10⁶/mL for labeling with BATDA reagent (Perkin Elmer AD0116). Manufacturer instructions were followed for labeling of the target cells. After labeling cells were washed 3x with PBS, and were 25 resuspended at 0.5-1.0x10⁵/mL in culture media. To prepare the background wells an aliquot of the labeled cells was put aside, and the cells were spun out of the media. 100 μ l of the media was carefully added to wells in triplicate to avoid disturbing the pelleted cells. 100 μ l of BATDA labeled cells were added to each well of the 96-well plate. Wells were saved for spontaneous release from target cells, and wells were prepared for max lysis of target cells by 30 addition of 1% Triton-X. Monoclonal antibodies or TriNKETs against the tumor target of interest were diluted in culture media, 50 μ l of diluted mAb or TriNKET was added to each well. Rested and/or activated NK cells were harvested from culture, cells were washed, and were resuspended at 10⁵-2.0x10⁶/mL in culture media depending on the desired effector to

target cell ratio (E:T). 50 µl of NK cells was added to each well of the plate to make a total of 200 µl culture volume. The plate was incubated at 37 °C with 5% CO₂ for 2-3 hours before developing the assay.

[00203] After culturing for 2-3 hours, the plate was removed from the incubator and the cells were pelleted by centrifugation at 200g for 5 minutes. 20 µl of culture supernatant was transferred to a clean microplate provided from the manufacturer and 200 µl of room temperature europium solution was added to each well. The plate was protected from the light and incubated on a plate shaker at 250 rpm for 15 minutes. The plate was read using either Victor 3 or SpectraMax i3X instruments. % Specific lysis was calculated as follows: % Specific lysis = ((Experimental release – Spontaneous release) / (Maximum release – Spontaneous release)) * 100%.

[00204] TriNKETs mediated cytotoxicity of human NK cells towards the CD33-positive human cancer cell lines. Rested human NK cells were mixed with MV4-11 cancer cells (FIG. 40A), rested human NK cells were mixed with Molm-13 cancer cells (FIG. 40B), and rested human NK cells were mixed with THP-1 cancer cells (FIG. 40C). TriNKETs (*e.g.*, CD33-TriNKET-C26 and CD33-TriNKET-F04) are able to enhance cytotoxic activity of rested human NK cells in a dose-responsive manner towards the cancer cells. The dotted line indicates cytotoxic activity of rested NK cells without the TriNKETs. CD33 monoclonal antibody showed reduced efficacy on MV4-11 cells, which express CD64, but at a lower level than THP-1 cells. CD33 monoclonal antibody showed good efficacy on Molm-13 cells, which do not express CD64. CD33 monoclonal antibody showed no effect on THP-1 cells, which have a high CD64 level.

[00205] TriNKET-mediated lysis of CD33-positive human cancer cells Molm-13 was assayed. Rested human NK cells were mixed with Molm-13 cancer cells at 5:1 ratio (FIG. 41), and TriNKETs (*e.g.*, CD33-TriNKET-A49, CD33-TriNKET-A44, CD33-TriNKET-C26, and CD33-TriNKET-E79) were able to enhance the cytotoxic activity of rested human NK cells in a dose-responsive manner towards the cancer cells. The dotted line indicates cytotoxic activity of rested NK cells without TriNKETs.

Example 12 – The advantage of TriNKETs in treating cancers with high expression of FcR, or in tumor microenvironments with high levels of FcR

[00206] Monoclonal antibody therapy has been approved for the treatment of many cancer types, including both hematological and solid tumors. While the use of monoclonal antibodies in cancer treatment has improved patient outcomes, there are still limitations.

Mechanistic studies have demonstrated monoclonal antibodies exert their effects on tumor growth through multiple mechanisms including ADCC, CDC, phagocytosis, and signal blockade amongst others.

[00207] Most notably, ADCC is thought to be a major mechanism through which monoclonal antibodies exert their effect. ADCC relies on antibody Fc engagement of the low-affinity Fc γ RIII (CD16) on the surface of natural killer cells, which mediate direct lysis of the tumor cell. Amongst Fc γ R, CD16 has the lowest affinity for IgG Fc, Fc γ RI (CD64) is the high-affinity FcR, and binds about 1000 times stronger to IgG Fc than CD16.

[00208] CD64 is normally expressed on many hematopoietic lineages such as the myeloid lineage, and can be expressed on tumors derived from these cell types, such as acute myeloid leukemia (AML). Immune cells infiltrating into the tumor, such as MDSCs and monocytes, also express CD64 and are known to infiltrate the tumor microenvironment. Expression of CD64 by the tumor or in the tumor microenvironment can have a detrimental effect on monoclonal antibody therapy. Expression of CD64 in the tumor microenvironment makes it difficult for these antibodies to engage CD16 on the surface of NK cells, as the antibodies prefer to bind the high-affinity receptor. Through targeting two activating receptors on the surface of NK cells, TriNKETs may be able to overcome the detrimental effect of CD64 expression on monoclonal antibody therapy.

FcR γ I (CD64) expression on three AML cell lines

[00209] An *in vitro* culture system was developed to test the activity of TriNKETs and monoclonal antibodies against tumors with high and low levels of CD64 surface expression. Molm-13 and THP-1 are two human AML cell lines which have similar expression of surface CD33, but Molm-13 cells do not express CD64, while THP-1 cells express CD64 on their surface (FIGs. 38A – 38C). Using monoclonal antibodies or TriNKETs directed to target CD33, the effect of CD64 expression by the tumor on monoclonal antibody or TriNKET therapy was tested. FIGs. 38A – 38C showed the expression of the high-affinity FcR γ I (CD64) on three human AML cells lines, Molm-13 cell line (FIG. 38A), MV4-11 cell line (FIG. 38B), and THP-1 cell line (FIG. 38C). Molm-13 cells do not express CD64, while MV4-11 cells have a low level, and THP-1 have a high level of cell surface CD64.

TriNKETs have an advantage in targeting tumor cells with high surface expression of FcRs

[00210] FIGs. 39A – 39B show monoclonal antibody or TriNKET mediated activation of human NK cells in co-culture with either Molm-13 (FIG. 39B) or THP-1 (FIG. 39A) cells. A
5 monoclonal antibody against human CD33 demonstrated good activation of human NK cells, in the Molm-13 co-culture system as evidenced by increased CD107a degranulation and IFN γ production. The monoclonal antibody has no effect on the THP-1 co-culture system, where high levels of CD64 are present on the cancer cells. Interestingly, TriNKETs are effective against both Molm-13 (FIG. 39B) and THP-1 (FIG. 39A) cells, indicating that TriNKETs are
10 able to overcome binding to CD64 on the tumor, and effectively target NK cells for activation. Dual targeting of two activating receptors on NK cells provided stronger specific binding to NK cells. Monoclonal antibodies, which only target CD16 on NK cells, can be bound by other high-affinity FcRs, and prevent engagement of CD16 on NK cells. As show in FIG. 39C, TriNKETs also efficiently mediated activation of rested human NK cells in co-
15 culture with MV4-11 human AML cells.

TriNKETs demonstrate efficacy on AML cell lines regardless of Fc γ RI expression

[00211] FIGs. 40A – 40C show human NK cytotoxicity assays using the three human AML cell lines as targets. A monoclonal antibody against CD33 showed good efficacy against Molm-13 cells (FIG. 40B), which do not express CD64. MV4-11 cells (FIG. 40A),
20 which express CD64, but at a lower level than THP-1, showed reduced efficacy with the monoclonal anti-CD33. THP-1 cells (FIG. 40C) showed no effect with monoclonal anti-CD33 alone. Regardless of CD64 expression on the tumor cells, TriNKETs were able to mediate human NK cell responses against all tumor cells tested here.

[00212] FIGs. 40A – 40C show that THP-1 cells were protected against monoclonal
25 antibody therapy, due to high levels of high-affinity FcR expression on their surface. TriNKETs circumvented this protection by targeting two activating receptors on the surface of NK cells. Cytotoxicity data correlated directly to what was seen in the co-culture activation experiments. TriNKETs were able to circumvent protection from mAb therapy seen with THP-1 cells, and induce NK cell mediated lysis despite high levels of FcR.

30 **Example 13 - Killing of normal myeloid and normal B cells in PBMC cultures:**
TriNKETs provide better safety profile through less on-target off-tumor side effects

[00213] Natural killer cells and CD8 T cells are both able to directly lyse tumor cells, although the mechanisms through which NK cells and CD8 T cells recognize normal self from tumor cells differ. The activity of NK cells is regulated by the balance of signals from activating (NCRs, NKG2D, CD16, *etc.*) and inhibitory (KIRs, NKG2A, *etc.*) receptors. The
5 balance of these activating and inhibitory signals allow NK cells to determine healthy self-cells from stressed, virally infected, or transformed self-cells. This “built-in” mechanism of self-tolerance, will help protect normal healthy tissue from NK cell responses. To extend this principle, the self-tolerance of NK cells will allow TriNKETs to target antigens expressed both on self and tumor without off tumor side effects, or with an increased therapeutic
10 window.

[00214] Unlike natural killer cells, T cells require recognition of a specific peptide presented by MHC molecules for activation and effector functions. T cells have been the primary target of immunotherapy, and many strategies have been developed to redirect T cell responses against the tumor. T cell bispecifics, checkpoint inhibitors, and CAR-T cells have
15 all been approved by the FDA, but often suffer from dose-limiting toxicities. T cell bispecifics and CAR-T cells work around the TCR-MHC recognition system by using binding domains to target antigens on the surface of tumor cells, and using engineered signaling domains to transduce the activation signals into the effector cell. Although effective at eliciting an anti-tumor immune response these therapies are often coupled with
20 cytokine release syndrome (CRS), and on-target off-tumor side effects. TriNKETs are unique in this context as they will not “override” the natural systems of NK cell activation and inhibition. Instead, TriNKETs are designed to sway the balance, and provide additional activation signals to the NK cells, while maintaining NK tolerance to healthy self.

[00215] PBMCs were isolated from whole blood by density gradient centrifugation. Any
25 contaminating red blood cells were lysed by incubation in ACK lysis buffer. PBMCs were washed 3x in PBS, and total PBMCs were counted. PBMCs were adjusted to 10^6 /mL in primary cell culture media. 1mL of PBMCs were seeded into wells of a 24 well plate, the indicated TriNKETs or mAbs were added to the PBMC cultures at 10 μ g/mL. Cells were cultured overnight at 37°C with 5% CO₂. The following day (24 hours later) PBMCs were
30 harvested from culture and prepared for FACS analysis. The percentage of CD45+; CD19+ B cells and CD45+; CD33+; CD11b+ myeloid cells was analyzed over the different treatment groups.

[00216] FIG. 42A shows that B cells (CD33-negative) from a healthy donor were unaffected by CD33-targeting TriNKET. PBMCs treated with TriNKETs-targeting CD33

showed no effect on CD45+, CD3-, CD56- lymphocyte population. FIG. 42B shows that autologous CD33+ myeloid cells were protected from CD33-targeting TriNKET-mediated NK cell responses, and, therefore, were resistant to TriNKET-mediated lysis. In these cultures, the frequency of CD45+, CD33+, CD11b+ myeloid cells were unchanged upon
5 incubation with CD33-targeting TriNKETs.

INCORPORATION BY REFERENCE

[00217] The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes.

10

EQUIVALENTS

[00218] The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing
15 description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.

CLAIMS

WHAT IS CLAIMED IS:

1. A protein comprising:
 - (a) a first antigen-binding site of an immunoglobulin molecule that binds NKG2D;
 - (b) a second antigen-binding site of an immunoglobulin molecule that binds CD33; and
 - (c) an antibody Fc domain or a portion thereof sufficient to bind CD16.
2. The protein according to claim 1, wherein the first antigen-binding site binds to human and non-human primate NKG2D.
3. The protein according to claim 1 or 2, wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain.
4. A protein according to claim 3, wherein the heavy chain variable domain and the light chain variable domain are present on the same polypeptide.
5. The protein according to any one of claims 3-4, wherein the second antigen-binding site comprises a heavy chain variable domain and a light chain variable domain.
6. The protein according to claim 5, wherein the heavy chain variable domain and the light chain variable domain of the second antigen-binding site are present on the same polypeptide.
7. The protein according to claim 5 or 6, wherein the light chain variable domain of the first antigen-binding site has an amino acid sequence identical to the amino acid sequence of the light chain variable domain of the second antigen-binding site.
8. The protein according to any one of claims 1-7, wherein the first antigen-binding site comprises
 - (a) a heavy chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:54, a heavy chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:55, and a heavy chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:56;
 - (b) a heavy chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:57, a heavy chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:58, a heavy chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:59, a light chain

CDR1 sequence identical to the amino acid sequence of SEQ ID NO:60, a light chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:61, and a light chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:62;

(c) a heavy chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:63, a heavy chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:64, a heavy chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:65, a light chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:66, a light chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:67, and a light chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:68;

(d) a heavy chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:71, a heavy chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:72, a heavy chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:73, a light chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:74, a light chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:75, and a light chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:76;

(e) a heavy chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:87, a heavy chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:88, a heavy chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:89, a light chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:90, a light chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:91, and a light chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:92; or

(f) a heavy chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:135, a heavy chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:136, a heavy chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:137, a light chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:138, a light chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:139, and a light chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:140.

9. The protein according to claim 8, wherein the first antigen-binding site comprises a heavy chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1.

10. The protein according to claim 8, wherein the first antigen-binding site comprises a heavy chain variable domain amino acid sequence at least 95% identical to the amino acid

sequence of SEQ ID NO:41 and a light chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:42.

11. The protein according to claim 8, wherein the first antigen-binding site comprises a heavy chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:43 and a light chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:44.

12. The protein according to claim 8, wherein the first antigen-binding site comprises a heavy chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:45 and a light chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:46.

13. The protein according to claim 8, wherein the first antigen-binding site comprises a heavy chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:69 and a light chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:70.

14. The protein according to claim 8, wherein the first antigen-binding site comprises a heavy chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:85 and a light chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:86.

15. The protein according to claim 8, wherein the first antigen-binding site comprises a heavy chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:133 and a light chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:134.

16. The protein of claim 1 or 2, wherein the first antigen-binding site is a single-domain antibody.

17. The protein of claim 16, wherein the single-domain antibody is a V_HH fragment or a V_{NAR} fragment.

18. The protein according to any one of claims 1-2 and 16-17, wherein the second antigen-binding site comprises a heavy chain variable domain and a light chain variable domain.

19. The protein according to claim 18, wherein the heavy chain variable domain and the light chain variable domain of the second antigen-binding site are present on the same polypeptide.

20. The protein according to any one of claims 1-19, wherein the second antigen-binding site comprises

(a) a heavy chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:95, a heavy chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:96, a heavy chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:97, a light chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:98, a light chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:99, and a light chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:100;

(b) a heavy chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:103, a heavy chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:104, a heavy chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:105, a light chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:106, a light chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:107, and a light chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:108;

(c) a heavy chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:111, a heavy chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:112, a heavy chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:113, a light chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:114, a light chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:115, and a light chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:116;

(d) a heavy chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:119, a heavy chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:120, a heavy chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:121, a light chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:122, a light chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:123, and a light chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:124; or

(e) a heavy chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:127, a heavy chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:128, a heavy chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:129, a light chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:130, a light chain

CDR2 sequence identical to the amino acid sequence of SEQ ID NO:131, and a light chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:132.

21. The protein according claim 20, wherein the second antigen-binding site comprises a heavy chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:93 and a light chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:94.

22. The protein according claim 20, wherein the second antigen-binding site comprises a heavy chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:101 and a light chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:102.

23. The protein according claim 20, wherein the second antigen-binding site comprises a heavy chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:109 and a light chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:110.

24. The protein according claim 20, wherein the second antigen-binding site comprises a heavy chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:117 and a light chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:118.

25. The protein according claim 20, wherein the second antigen-binding site comprises a heavy chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:125 and a light chain variable domain amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:126.

26. The protein according to any one of claims 1-4 and 8-15, wherein the second antigen-binding site is a single-domain antibody.

27. The protein of claim 26, wherein the second antigen-binding site is a V_HH fragment or a V_{NAR} fragment.

28. The protein according to any one of the preceding claims, wherein the protein comprises a portion of an antibody Fc domain sufficient to bind CD16, wherein the antibody Fc domain comprises hinge and CH2 domains.

29. The protein according to claim 28, wherein the antibody Fc domain comprises hinge and CH2 domains of a human IgG1 antibody.
30. The protein according to claim 28 or 29, wherein the Fc domain comprises an amino acid sequence at least 90% identical to amino acids 234-332 of a human IgG1 antibody.
31. The protein according to any one of claims 28-30, wherein the Fc domain comprises an amino acid sequence at least 90% identical to the Fc domain of human IgG1 and differs at one or more positions selected from the group consisting of Q347, Y349, T350, L351, S354, E356, E357, K360, Q362, S364, T366, L368, K370, N390, K392, T394, D399, S400, D401, F405, Y407, K409, T411, and K439.
32. A formulation comprising the protein according to any one of the preceding claims and a pharmaceutically acceptable carrier.
33. A host or *in vitro* cell comprising one or more nucleic acids encoding the protein according to any one of claims 1-31.
34. Use of the protein according to any one of claims 1-31 in the manufacture of a medicament for directly and/or indirectly enhancing CD33-expressing tumor cell death by exposing the tumor cell and a natural killer cell to an effective amount of the protein wherein the first antigen-binding domain activates NKG2D.
35. Use of the protein according to any one of claims 1-31 or the formulation according to claim 32 in the manufacture of a medicament for treating CD33-expressing cancer wherein the first antigen-binding domain activates NKG2D.
36. The use of claim 35, wherein the CD33-expressing cancer is AML, myelodysplastic syndromes, chronic myelomonocytic leukemia, myeloid blast crisis of chronic myeloid leukemia, or ALLs.